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ABSTRACT 
 
qPCR VALIDATION OF IN VIVO DIAGNOSTIC IMPORTANCE AND 
REGULATION BY ESTROGEN FOR CHRNA5 ISOFORM EXPRESSION IN 
BREAST CANCER  
Emine Sıla Özdemir 
MSc. in Molecular Biology and Genetics 
Supervisor: Asst. Prof. Dr. Özlen Konu 
September 2014 
Breast cancer has multiple molecular subtypes; normal-like, basal-like, luminal A, 
luminal B and HER2 positive depending on receptor status of tumor cells. Cancer 
therapy is tailored according to the type of cancer; hence finding new diagnostic 
markers is important to decide on the best treatment approach. Cholinergic nicotinic 
receptor alpha 5 (CHRNA5) is one of the subunits of nicotinic acetylcholine 
receptors with significant roles in addiction and cancer. In the present study, 
CHRNA5 has been validated as an estrogen and/or Estrogen receptor (ER) 
modulated nicotinic acetylcholine receptor by qPCR in in vitro and in vivo in breast 
cancer samples. CHRNA5 isoform expression was measured using in vitro cell 
culture studies in which ER- and ER+ cell lines treated with different doses of 
estradiol (E2); MCF7 cell line was exposed to long-term E2 depletion, in another 
experiment it was treated with tamoxifen (4-OHT), an ER antagonist, and with or 
without E2. We found that all CHRNA5 isoforms exhibited increased expression in 
response to E2 dose-dependently in the ER+ MCF7 cell line while in the ER- MDA-
MB-231 cell line CHRNA5 isoform expression response was variable in direction 
and magnitude. CHRNA5 isoform expression in general steadily decreased in ER+ 
cell line MCF7 after 4-OHT treatment. After six months of E2 depletion, ER+ MCF7 
cell line had increased CHRNA5_v3 isoform and ESR1 (ER gene) mRNA 
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expression. In vivo, a human breast cancer cDNA panel was scanned with specially 
designed primers with qPCR using a custom-written GUI in MATLAB. It was found 
that CHRNA5, showing a statistically significant difference between normal and 
tumor cDNA, was a good candidate gene in diagnosis of breast cancer. CHRNA_v3 
was able to distinguish between ER+ vs ER- breast tumor samples. We also 
addressed whether CHRNA5 isoforms exhibited differences in distinguishing tumor 
stage, and HER2 status. Our findings showed that expression of CHRNA5 isoforms 
were correlated with each other and regulated by E2 in breast cancer depending on 
ER receptor status. 
Keywords: Breast cancer, CHRNA5, estrogen, estrogen depletion, tamoxifen, 
molecular subtype. 
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ÖZET 
 
MEME KANSERİNDE CHRNA5 İSOFORM İFADESİNİN IN VIVO 
TANISAL ÖNEMİ VE ÖSTROJENLE DÜZENLENMESİNIN qPCR İLE 
DOĞRULANMASI 
Emine Sıla Özdemir 
Moleküler Biyoloji ve Genetik Yüksek Lisansı  
Tez Danışmanı: Yrd. Doç. Dr. Özlen Konu 
Eylül 2014  
Meme kanserinin birden çok alt tipi bulunmaktadır; bunlar tümör hücresinin reseptör 
durumuna bağlı olan normal benzeri, bazal benzeri, luminal A, luminal B ve HER2 
pozitiftir. Kanser tedavisi, kanser tipine göre belirlenir; bu da teşhis amaçlı yeni bir 
markör bulmanın en iyi tedavi yöntemini bulmaktaki önemini göstermektedir. 
Kolinerjik reseptör nikotinik alfa 5 (CHRNA5) nikotinik asetilkolin reseptörlerinin 
bir alt birimi olup bağımlılık ve kanserde önemli rol oynamaktadır. Bu çalışmada, 
CHRNA5’in östrojenle ve/veya östrojen reseptörü ile modüle edilen bir reseptör 
olduğu meme kanseri örneklerinde in vivo ve in vitro qPCR doğrulama çalışmalarıyla 
gösterilmiştir. CHRNA5 izoform ifadesi farklı dozda estradiol E2 uygulamasına 
maruz bırakılan ER- ve ER+ hücre hatlarında hücre kültürü çalışmalarıyla ölçülmüş; 
MCF7 hücre hattı uzun süreli E2 açlığına maruz bırakılmış ve diğer bir deneyde ise 
E2 varlığında ve yokluğunda bir ER antagonisti olan tamoxifen (4-OHT) 
uygulanmasına maruz bırakılmıştır. E2 tedavisinden sonra ER+ MCF7 hücre hattında 
doza bağlı olarak CHRNA5 izoform ifadesinin arttığı, ER- MDA-MB 231 hücre 
hattında ise CHRNA5 izoform ifadesinin yön ve miktar açısından değişkenlik 
gösterdiği bulgulanmıştır. CHRNA5 izoform ifadesi genel olarak ER+ MCF7 hücre 
hattında 4-OHT tedavisi sonucunda azalmıştır. Altı aylık E2 yokluğundan sonra ER+ 
hücre hatlarında CHRNA5_v3 ve ESR1 (ER geni) ifadesinin arttığı gözlenmiştir. In 
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vivo, bir insan meme kanseri cDNA paneli, özel olarak tasarlanmış primerlerle qPCR 
yöntemi ve MATLAB’da özel yazılmış GUI uygulaması kullanılarak taranmıştır. 
Normal ve tümör cDNA’leri arasında istatistiksel olarak önemli bir ifade farklılığı 
gösteren CHRNA5 geninin, meme kanseri teşhisinde önemli bir biyobelirteç olduğu 
bulgulanmıştır. Ayrıca, CHRNA5_v3 izoformu ER+ ve ER- meme tümörü 
örneklerini ayırt edebilmektedir. CHRNA5 izoformlarının miktarının stage ve HER2 
statusüne göre nasıl değiştiği de test edilmiştir. Bulgularımız CHRNA5 
izoformlarının birbirleriyle korale olduğuğunu ve meme kanserinde reseptör 
statüsüne bağlı olarak E2 tarafından regüle edildiğini göstermiştir. 
Anahtar sözcükler: Meme kanseri, CHRNA5, östrojen, östrojen açlığı, tamoxifen, 
moleküler tip. 
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1.INTRODUCTION 
1.1 Breast Cancer 
Breast cancer is a cancer type initiated from mammary gland lobules that function in 
providing milk, and ducts that connect lobules to nipples 
1
. It is the worldwide 
second most common cancer type, and the reason of ~15% of cancer-related deaths 
in women 
2
. 
Breast cancer can be hereditary or sporadic. In hereditary breast cancer, the germline 
mutations that patients inherited increase susceptibility of developing breast cancer. 
BRCA1 and BRCA2 are the main genes involved in breast cancer, however, PTEN 
and TP53 mutations also are effective in breast cancer development 
3
. On the other 
hand, sporadic breast cancer occurs as a result of the accumulation of mutations in 
somatic tissue. More than 80% of women who face with breast cancer do not have a 
previous complaint on the disease occurrence in the family; risk factors include age 
and diet 
3
. 
Tumorigenesis, the transformation from a normal cell to a malignant cell, basically 
occurs in three steps 
4
: First, normal cell changes into a lesion and then lesion 
becomes malignant. The last step occurs when the malignant lesion undergoes 
metastasis.  
The genes and steps involving mammary gland tumorigenesis are explained in Figure 
1.1. A breast stem cell divides asymmetrically, and then there could be mutation in a 
gene involving breast cancer susceptibility. It is possible that the two events could be 
simultaneous. These genes might involve cell cycle regulation and the mutation of in 
one or more of them encourages proliferation 
5
. 
 
2 
 
 
Figure 1.1:  A model for breast carcinogenesis.  
 (Reprinted from Foulkes, 2008, with permission from Nature Publishing Group) 
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1.1.1 Classification and Subtypes in Breast Cancer 
Breast cancer is a heterogeneous disease hence it requires to be categorized 
effectively for more accurate diagnosis of subtypes and identification of personalized 
therapeutic strategies. Breast cancer classification can be done considering different 
aspects of tumor biology, e.g., histological, molecular. Histological subtypes of 
breast cancer indicate the location of tumor initiation site and state as well as the 
status of invasiveness of cancer. The histological subtypes can be distinguished via in 
situ studies as invasive ductal, ductal and invasive lobular carcinomas 
6
. 
Grade of a breast cancer tumor defines how differentiated the tumor tissue is from 
normal breast tissue. If the tumor is well differentiated it is called as low-grade and 
they are more similar to normal tissue than high-grade tumors that are not well 
differentiated 
7
.  
Molecular classification of breast cancer on the other hand considers receptor status 
of tumor tissue as the primary factor. There are three types of receptors on breast 
cancer tumor cells which could be associated with the character of tumor. Estrogen 
Receptor 1 (ER), Human Epidermal growth factor Receptor 2 (HER2) and 
Progesteron Receptor (PR) are these three receptors that may take part in the 
proliferation and maintenance of tumor cells.  
Recent studies performed with  microarrays also have led to identification of 
expression profiles that categorize molecular subtypes; these have been basically 
classified as normal-like, luminal A, luminal B, HER2+ and basal-like type 
8
. Basal-
like contains triple negative cancers that do not include any of the indicated three 
receptors. Luminal types are ER+, however they differ by the level of gene 
expression of HER2, luminal A subtypes do not express HER2, while luminal B 
subtypes are HER2+ 
9
. HER2+ type breast cancer as the name implies are positive 
for HER2 
8
; ERBB2/HER2 positive tumors grow and spread more  aggressively 
similar to basal-like subtypes 
10
. In Table 1.1 molecular subtypes are summarized. 
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Table 1.1: Classification of molecular subtypes 
Subtype ER PR HER2 
Basal - - - 
Luminal A + + or - - 
Luminal B + + or - + 
HER2+ - - + 
 
1.1.1.1 Receptor Status Defining Diagnosis and Survival 
The estrogen receptor (ER) has an important role in breast cancer development and 
progression. Current work on gene expression profiles seem to be altered according 
to hormone receptor status of the breast cancer 
11
. Microarray studies show existence 
of gene sets correlating with receptor status thus allowing for interpreting subtypes 
upon examining the expression of these genes.  ER status, in addition, has an impact 
on the DNA methylation state of some genes such as FAM124B, NAV1, and PER1 
in breast cancer 
12
. 
Genetic and epigenetic alterations in ER + tumors increase the sensitivity to 
endocrine therapy, yet ER- tumors are known as hormone independent 
12
. ER- 
tumors do not have a functional protein to which the hormone estrogen will bind. 
There is no need for estrogen for the growth of ER- breast cancer, and usually they 
do not halt growing upon treatment with hormones that prevent estrogen from 
binding. Therefore, ER- breast tumors are considered as more aggressive 
13
. Studies 
show that ER- breast cancers do not have ER mRNA. The lack of ER is not a result 
of deletions or other structural changes in the ER gene. CpG island methylation is 
thought to be one of the alternatives in blockage of the transcription of the ER gene 
in ER – breast cancers 14. 
Progesterone receptor (PR) is the mediating factor for progesterone’s effects in the 
development of the mammary gland and the progression of the breast cancer. PR is 
5 
 
expressed in more than half of the ER + breast cancer, and estrogen signaling is 
necessary to induce PR expression 
15
. It was found that some oncogenic pathways 
including PI3 K/Akt/mTOR, were more active in both ER-/PR- and ER+/PR- 
compared to ER+/PR+ tumors. PR- tumors can be considered more aggressive and 
invasive 
15
.  
The ERBB2/HER2 gene is overexpressed in 20% - 30% of invasive breast 
carcinomas; a positive HER2 status is associated with improvement of metastatic 
potential and decreased overall survival. In addition, patients with HER2+ tumors are 
less responsive to tamoxifen treatment than patients with HER2- tumors 
16
. 
1.1.2 Risk Factors  
Risk factors causing breast cancer can be hereditary as well as environmental. 
Moreover, main risk factors such as gender and age are not modifiable. Family 
history is also an important risk factor, with increasing susceptibility to breast cancer 
in women with one or more relatives with breast cancer. 
Conditions triggering other risk factors including postmenopausal obesity, smoking 
and alcohol consumption, use of estrogen and progesterone menopausal hormones 
can be intervened. For example, use of hormones as therapy increases the cell 
proliferation and promotes susceptibility to DNA damage and induces breast cancer 
cell growth 
17
.  Recent epidemiological studies have focused on how much a factor 
hormonal therapy is in breast cancer risk and they concluded that recent and long-
term use of menopausal hormone therapy has a relative risk value between 1.1-2.0 
2
. 
Avoding such modifiable risk factors may help reduce the risk of breast cancer. 
Table 1.2 summarizes general breast cancer risk factors with the relative likelihood 
of the risk 
2
. 
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Table 1.2: Breast cancer risk factor and relativity of the risk 
2
 
Relative Risk Factor 
>4.0 Age, 
Certain inherited genetic mutations 
(BRCA1-2), 
Personal history of early onset 
2.1-4.0 Exposure to high-dose radiation, 
One first degree relative with breast 
cancer 
1.1-2.0 Alcohol consumption, 
Height, 
Obesity, 
Long-term and recent use of hormone 
therapy 
1.2 Estrogen (E2) Signaling in Breast Cancer        
Estrogens are steroid hormones found primarily in females. Serum estrogen level in 
premenopausal women is high, while its level decreases in postmenopausal women. 
Estrogen can be provided both endogenously or exogenously. Estrogen is primarily 
produced by ovaries during menstrual life endogenously. Exogenous sources include 
hormone-replacement therapies and oral contraceptive usage. The small amount of 
estrogen present after menopause comes from extragonadal tissues like muscles, fat 
and liver 
18
.  
It is known that estrogens are responsible for the initiation and growth of breast 
cancer. The exact mechanism is still complex but estrogens lead to the development 
of mammary cancer with proliferative effects 
19
. Metabolism of estrogen and its 
metabolites are affected by genetic and environmental factors and breast cancer 
initiation and growth can relate to estrogen and its metabolites. 
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There are other ligands besides E2 which can trigger ER pathway; however they may 
have antagonistic effect on cell proliferation. Phytoestrogens and genistein are plant 
derived compounds that are structurally similar to E2.  Although phytoestrogens 
induce estrogen responsive genes, their anti-proliferative and apoptotic effects are 
mediated through the estrogen receptor 
20,21
. 
1.2.1 Genomic and Nongenomic Signaling 
Estrogen stimulation triggers two pathways in general: genomic and nongenomic 
signaling. Estrogen molecule can pass through membrane because of its steroid 
structure. In ER+ cells, estrogen and ER located in nucleus interact and form a 
ligand-receptor complex. After binding of estrogen, ER dimerizes using two types of 
estrogen receptors, ER-α and ER-β, with ability to form homo- or heterodimers after 
binding of ligand (estrogen). This complex then binds to specific response elements 
known as estrogen response elements (EREs) located in the promoters of target 
genes 
22,23
. However, there are cases in which ER does not directly bind to DNA to 
regulate gene expression. This occurs through secondary messenger triggering a set 
of transcription factors in nucleus 
22
. 
E2 modulated classical genomic signaling pathway includes direct binding of ER to 
DNA via ERE. Transferred E2-ER complex from the plasma to the nucleus recruits 
transcriptional machinery and other cofactors to specific DNA target sequences of 
estrogen-responsive gene promoters 
24
. However, it is known that approximately one 
third of the genes in humans that are regulated by ERs do not contain ERE-like 
sequences 
25
. Molecular mechanism behind this phenomenon still is not fully 
understood.  
Nongenomic ER signaling pathway alters gene expression with the help of secondary 
messengers, E2-ER complex does not directly enter nucleus 
24
. Cytoplasmic ER and 
E2 interaction triggers mobilization of intracellular calcium and cAMP production. 
E2 can activate MAPK signaling pathway with the nongenomic actions in several 
cell types including breast cancer 
26
. E2 also triggers the phosphoinositol (PI) 3-
kinase signaling pathway in breast cancer cell 
27
. Additionally, E2 activated 
membrane associated ERs come in close contact with metabotropic glutamate 
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receptors (mGluRs), turning on mGluR signaling without glutamate. Protein kinase 
cascades including PKA,PKC, and tyrosine kinases pathways can mediate the non-
genomic ER pathway 
24
. 
Figure 1.2 shows a representation of genomic and nongenomic ER signaling 
pathways. 
 
Figure 1.2: Representation of genomic and nongenomic ER signaling pathway 
1. Genomic signaling pathway, 2. ERE-independent genomic signaling pathway, 3. Nongenomic 
signaling pathway (Reproduced with permission from Björnström et al., 2005 Copyright 
Massachusetts Medical Society) 
1.2.2 4-OHT and Breast Cancer   
Tamoxifen (4-OHT) is an agent commonly used as an anti-estrogen treatment for 
hormone-dependent breast cancer patients. As mentioned earlier E2 induces cell 
proliferation in ER+ breast cancer cells and 4-OHT, an ER antagonist, blocks the 
binding of E2 to ER 
28,29
. 4-OHT binds to the ER and affect the position of helix 12, 
preventing ER transcriptional activation 
30
. 
It is also thought that E2 can modulate a pathway that triggers the invasiveness of 
tumor cells, so inhibition of E2 pathway is crucial for the therapy of both early and 
advanced breast cancer 
31
. 
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Although 4-OHT/tamoxifen therapy is very efficient and beneficial for patients, 
eventually tamoxifen resistance develops in tumor cells. It is also known that 
tamoxifen resistance can promote EMT-like behavior 
32,33
.   
1.2.3 Effects of Long-term E2 Depletion on Estrogen Receptors 
Endocrine therapies including long term estrogen depletion (LTED) are the most 
effective systemic treatment of ER+ breast cancer. However, tumor cells can develop 
resistance to endocrine therapies. Indeed, acquired resistance is not related to the 
conversion of ER+ cells to ER- cells; hence changes in ER expression are thought to 
be main reason of resistance 
34
. Previous research supports that resistance is acquired 
by molecular events trigger constitutive activation of ER and growth factor signaling 
pathway 
35
. Long term estrogen depletion may cause an increase in growth factor 
receptor levels, such that ER could also be significantly overexpressed 
36
. 
As a pilot study for hypothesis generation, we have analyzed a part of a microarray 
study that focused on effects of long-term estrogen depletion on transcriptome by 
using GEO2R 
36
. Figure 1.3 shows ESR1 expression in 3, 15 days and three months 
of long-term estrogen depletion (LTED) time course in an ER+ cell line. 
 
Figure 1.3: GEO2R analysis of GSE20361 dataset consisting of initial and three months long 
estrogen depleted ER+ cell line for ESR1 (ER) gene. 
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It is apparent that LTED leads to an upregulation in expression of ER mRNA levels; 
this increase could then be translated into protein and has potential to modify and 
compensate the lack of E2. Overexpression of ER could result in improved cell 
survival ability and the mediation of estrogen-independent growth, and end up with 
resistance to endocrine therapies in breast cancer patients 
37
. 
1.3 Cholinergic Receptor Nicotinic Alpha (CHRNA or nAChR)   
Nicotinic acetylcholine receptors or cholinergic nicotinic receptors are 
transmembrane proteins functioning as ligand-gated ion channels which can bind to 
acetylcholine (ACh) and nicotine. These ligands mainly found at the neuromuscular 
junction and in some neurons, also are present in non-neuronal cells 
38
. 
nAChRs have 2 different types of subunits; 9α (2-10), and  3β (2-4) subunits. 
Subunits form pentamers with a barrel like structure in the membrane around a 
central ion channel 
38
 (Figure 1.4). 
 
Figure 1.4: Schematic representation of nAChRs hetero (upper left) and homo-oligomer (botton 
left) complexes. (Reprinted from Weiland, 2000, with permission from Elsevier) 
 
Neuronal nAChRs have alternatively spliced forms which increase the diversity and 
number of receptor subtypes 
39
. Different subtypes may explain the variable 
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tolerance and addiction to nicotine or different release of neurotransmitters in 
different synapses 
40
.  
Besides nicotine addiction, nAChRs are effective in other disease, disorder and 
behaviors, such as Alzheimer’s Disease, Parkinson’s Disease, schizophrenia, 
epilepsy, and cancer 
38–40
. 
1.3.1 CHRNA5 and Cancer 
Neuronal nAChRs are also expressed in other tissues than lung; they can also be 
found in muscle, skin and pancreas 
41
. 
Chromosome 15q25.1 contains CHRNA3, CHRNA5 and CHRNB4 genes encoding 
α3, α5 and β4 subunits of nAChR 42. Genome-wide studies showed that these genes 
could be related to cancer development and progress. Studies mainly focused on lung 
cancer; a single nucleotide polymorphism (SNP) was found strongly associated with 
lung cancer susceptibility in CHRNA5 
42
. Recent studies have shown that nAChRs 
can accelerate cell proliferation, tumor invasion, and angiogenesis and can provide 
resistance against apoptosis 
43
. 
It was found that CHRNA5 was strongly upregulated in lung adenocarcinoma, 
compared to normal lung tissue. Five different transcripts isoforms of CHRNA5 
were identified in normal lung tissue. These isoforms form due to alternative splicing 
of the 5th exon. It was demonstrated that all mRNA isoforms were upregulated in 
lung adenocarcinoma with respect to normal lung tissue 
44
. Figure 1.5 shows 
alternative splicing of five CHRNA5 isoforms. 
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Figure 1.5: Representation of alternative splicing of CHRNA5 in lung. (Reprinted from Falvella 
et al., 2013, with permission from Oxford University Press) 
 
Also, it was demonstrated that CHRNA5 plays a role in modulating adhesion and 
motility in bronchial cells and in regulating p63 oncogene 
42
.  
Recent findings suggest that the expression of nAChR subunits including α5 encoded 
by CHRNA5 might be altered in human breast cancer tissues 
45
. Furthermore, some 
cohort and case–control studies have shown a positive association between cancer 
and smoking suggesting a connection between nAChRs and breast cancer 
43
. 
However, there is no comprehensive in vitro or in vivo study that examines the 
estrogen dependency of isoform specific expression in breast cancer. 
1.3.2 Regulation of CHRNA5 Expression  
CHRNA5 gene expression can be regulated by the changes in the density of 
regulatory elements or by indirect effects of changes in expression of other genes 
46,47
.  
IREB2, PSMA4, CHRNA5, CHRNA3 and CHRNB4 on the chromosome 15 are 
thought to be good candidates for lung cancer and they are co-regulated; their 
expression increases all together when expression of one of them is induced 
47
. 
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SNPs in the cis-regulatory elements may create or diminish cis-acting 
transcription/enhancer/suppressor factor binding sites, thus accumulation of SNP 
causing gain of function or alternative splicing induction are very common in 
genome. rs16969968 SNP on the sequence of CHRNA5 in exon 5, for example, 
triggers alternative splicing by creating new binding sites for transcription factors 
resulting the risk of nicotine dependence and cancer 
46
. 
1.3.3 Effects of E2 on Cholinergic Signaling 
E2 is thought as a factor affecting nAChRs expression; this also might give a clue to 
nAChRs-breast cancer relationship. Recent studies have showed that the ER 
signaling mediates upregulation of nAChR gene expression; nicotine and E2 both 
induced a9-nAChR expression in human breast cancer cells 
43,48
. 
The increase in nAChR expression with the effect of E2 can also be seen in protein 
level, however, it is found that E2-induced a9-nAChR protein upregulation can be 
detected in the ER+ cells compared with the ER- cells 
48
. Previous studies in our lab 
suggested that E2 treatment might increase expression of CHRNA5 based on 
analysis of microarray studies
49
 and by qPCR in a time-dependent manner 
50
 
however no study yet confirmed dose-dependence of increase in CHRNA5 
expression based on qPCR analysis of in vitro cell lines. Correlation between ER 
status and CHRNA5 expression in vivo was not addressed yet in the literature either.  
1.4 Alternative Splicing and Isoform Formation 
Alternative splicing is a post-transcriptional regulation in mRNA which might occur 
almost in all human genes controlling expression and function 
51
. The splicing 
process provides variation to gene expression. Alterations in splicing can affect the 
mRNA and protein products of a gene. Alternative splicing has an enormous 
contribution in protein diversity in metazoan organisms 
52
. Different patterns of 
alternative splicing exist (Figure 1.6): a cassette exon can be either included in the 
mRNA or excluded. Mutually exclusive exons may occur in the presence of two or 
more cassette exons. Alternative 5’_ and 3’_ splice sites permit the alterations in the 
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inclusion of a specific exon. CHRNA’s 5th exon represents an example in which 
alternative splice sites allow the lengthening or shortening of the exon 
44
.  
 
 
Figure 1.6: Patterns of alternative splicing. Grey boxes show sequences present final spliced 
mRNA. Stripped boxes are for representation of alternative RNA segments that may or may not 
be included in the mRNA.  
(Reprinted from Black, 2003, with permission from Annual Reviews) 
1.4.1 Importance of isoform expression patterns of genes in cancer 
Genes related to cancer susceptibility do not always have only one form, due to 
alternative splicing process same gene can be expressed in different ways. It is 
known that expression of these alternative spliced forms - isoforms- of genes can 
play roles in differentiation of cancer cells. Alternative splicing in the protein coding 
gene of mRNA gives rise to different proteins, therefore they differ in their activities 
51
. It is found that different isoforms of cancer related genes can help diagnosis of 
cancer 
44
. For example, different isoforms of CHRNA5 gene show significantly 
different expression level between normal lung and tumor tissue 
44
. Recent studies 
have reported that transcription factor XBP1 mRNA splicing activates autophagy in 
endothelial cells through upregulating Beclin1 transcription, a gene found as playing 
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a role in T-cell natural T-cell lymphoma 
51
. Alternative splicing has effects on 
different types of cancer, such as lymphoblastic leukemia cells, esophageal 
carcinoma lung cancer and breast cancer 
44,51,53
.  
1.4.2 Alternative Splicing and Breast Cancer  
Besides other types of cancers, alternatively spliced forms of genes may play a role 
in breast cancer initiation and growth. Recent studies revealed that certain isoforms 
are involved  in breast tumor formation from breast epithelial cells 
54
. 
CEACAM1 is a gene that plays a role in some cellular processes including cell-cell 
adhesion, differentiation, apoptosis and immune response;  its pre-mRNA undergoes 
alternative splicing generating isoforms consisting of an N-terminal and a variable 
number of multiple extracellular Ig-like domains, a transmembrane domain, and 
either short (CEACAM1-S) or long (CEACAM1-L) cytoplasmic domains. In normal 
breast, CEACAM1-S is the predominant isoform, while in breast cancer the S/L ratio 
highly decreases 
54
. 
Another gene TMEM16A forming Ca2+-activated Cl- channel has been found as 
alternatively spliced. Multiple protein isoforms of TMEM16A affect the voltage and 
Ca2+-dependence of the channels. Alternative splicing of exons 6b and 15 of 
TMEM16A are coordinated in several normal tissues and that this coordination 
increases in breast tumors 
55
.  
Chemokine CXCL12 signaling is strongly linked to tumor growth and metastasis in 
breast cancer and some other malignancies. Recent studies have showed that low 
levels of expression of CXCL12 correlates with worse prognosis in breast cancer 
with isoform-specific differences among α, β, γ, and δ isoforms 56. 
MNK2 gene encoding protein that is a substrate of the MAPK pathway and 
phosphorylates the translation initiation factor eIF4E is alternatively spliced forming 
two splicing isoforms Mnk2a, which contains a MAPK-binding domain, and Mnk2b, 
which lacks it. It is found that the Mnk2a isoform is downregulated in breast tumors 
57
. 
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Also it is known that expression of CHRNA5 gene isoforms show changes in cancer 
such as lung carcinoma, as represented in Figure 1.5. CHRNA5 might play a 
significant role in breast cancer initiation and growth 
43,44
. Therefore, it is possible 
that expression of CHRNA5 isoforms can change in breast cancer and its subtypes 
and this warrants further research. 
1.5 Isoform Expression Measurement Technologies  
It was mentioned that alternative spliced form of genes can play important role in 
some disease including cancer. This implies the importance of isoform expression 
measurement in diagnosis. Different isoforms involving tumor initiation or growth 
can also be used as a biomarker to obtain a reliable diagnosis without complex 
interventions such as biopsies or surgery. New technologies provide new techniques 
to determine and measure isoforms of gene of interest. 
1.5.1 Microarrays and Analysis Methods 
Microarray is one of the most common technology used detection and analysis on 
gene isoforms. Recent advances in microarray technology rendered the search for the 
expression of alternatively spliced form possible. 
In one study, arrays were designed using 2.5 million oligonucleotide selected probes 
to differentiate exon alternatives for ~17,250 human genes. ALEXA was designed 
for the analysis of AS microarrays. It used ~231,000 exon-intron probes, together 
with ~818,000 oligonucleotide exon-exon junctions probes and ~155,000 exon-
internal probes to  identify the differentially expressed exon alternatives
58
.  
1.5.2 qPCR Studies and Analysis Methods 
qPCR can be used to identification of  alternative spliced isoforms by designing 
primers or probes targeting the unique exon junctions of spliced isoforms. This 
method can be used to specifically amplify the long splicing isoform by using one 
primer in the alternative exon and an opposing primer in a constitutive exon. To 
detect the short splicing isoform, a boundary-spanning primer (BSP) for the sequence 
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covering the exon–exon junction with the reverse primer in a fundamental exon can 
be used 
59
. 
1.5.3 Northern Blots 
Northern blot technique is also used to identify alternative spliced isoforms.  RNA is 
run on agarose gel for separation, and then RNA in the gel is transferred onto 
membranes. 
Membrane is hybridized with probes to label RNA of interest, since the RNA is first 
separated by size, if one probe type can label different size of RNA on membrane it 
means RNA same gene has more than one product. This way the size of the products 
can be assessed and the presence of alternative splice products of the same gene or 
repetitive sequence motifs can be inferred 
60
. 
1.6 Diagnosis and Classifying Cancer with in vivo cDNA Expression 
Patterns  
Cancer diagnosis and subtype classification is very crucial to start therapy early. 
Studies on cancer diagnosis and subtyping should include a very large sample size to 
be sure of the results and interpretation of the data. Recently, tissue samples taken 
from cancer patients with different backgrounds are widely used in diagnosis studies. 
These tissues can be directly used by antibody labeling or staining for a certain set of 
proteins or gene products of cDNA isolated from these tissues can be used for further 
analysis. Expression studies, isoform analysis, clustering and subtyping can be 
performed using cDNA arrays with proper sample sizes. 
1.6.1 cDNA Panel Studies of Different Types of Cancer 
It is possible to find and utilize various cDNA panels commercially to use for in vivo 
validation of biomarker studies. These panels are produced for more than 20 different 
types of cancer including pancreas, colorectal, lung, brain, bladder and breast cancer 
(e.g., ORIGENE).  Arrays for only one type of cancer can be found for subtyping and 
diagnosis analysis; others are for a comparative cancer survey in which cDNA panels 
including different cancer types can be found.  
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In a hematopoietic cell and hematological malignancy study, cDNA array consisting 
of blood cancer samples, expression level of two related genes was examined and 
changes in their level between normal and cancer tissues were detected, also 
correlation between these two genes was spotted 
61
.  
A colon cancer array was used to detect isoform expression of gene of interest and 
most abundant isoform of the gene found in colon cancer was detected 
62
. 
1.6.2 Quantitative and Statistical Methods to Analyze cDNA Panels 
Primary method to analysis cDNA panels is quantitative polymerase chain reaction 
(qPCR). qPCR is a method mainly used for gene expression analysis studies, because 
it gives the user exact relative quantity of expression. However, in regular PCR it is 
hard to determine expression change exactly with agarose gel images.  
qPCR provides a cycle number (Ct or Cp) for each sample indicating in which cycle 
the amount of expression of the gene of interest exceed a certain threshold. 
Therefore, each Ct (threshold cycle) indirectly shows the level of expression when 
standardized by giving the opportunity to compare samples using these Ct values.  
cDNA panels including normal and tumor samples, different types of cancer or 
different stages or subtypes of same cancer can be analyzed with qPCR 
63
. 
However, qPCR only gives Ct values for each sample; in order to compare and 
interpret them, additional analyses are required. After normalizing Ct values can be 
normalized using ∆Ct or ∆∆Ct methods. In ∆∆Ct method, a relative quantification 
based on relative expression of a target gene versus reference gene can be obtained to 
investigate the physiological changes in gene expression 
64,65
. Upon normalization, 
statistical tests are used to interpret the significance of a difference in the expression 
level between groups in cDNA panel. ANOVA, t-test, ANCOVA, sign test are such 
statistical tests used to analyze raw data. Therefore, analyzing cDNA panels with 
large sample size will benefit from automation of data analysis 
66
.  
19 
 
In ∆∆Ct method, a relative quantification based on relative expression of a target 
gene versus reference gene can be gathered to interrogate the physiological 
fluctuations in gene expression 
64,65
. 
1.7 Tools for Expression Analysis  
Importance of expression studies and some different analysis methods to evaluate 
and interpret the data from gene or isoform expression experiments were mentioned 
above. Expression studies generally require large sample size to obtain reliable 
results, however, this makes the analysis of data difficult to handle. Software tools 
become important for an easy and reliable data analysis. While analyzing an 
expression data, raw data should be processed and the quality should be assessed. 
One of the most common expression data analysis tools that can be reached online is 
NCBI GEO. It is used not exactly for cDNA panel but for microarray analysis. The 
database has limited information about a microarray experiment (MIAME)-
compliant infrastructure that grasps completely annotated raw and processed data 
67
. 
GEO is currently the largest gene expression resource and it has grown exponentially 
each year. GEO analysis provides users a gene-centered representation that gives 
quantitative gene expression data for one gene across a DataSet. 
67
. 
Moreover, some other software can be used to cluster data according the gene 
expression. Hierarchical clustering can be performed to pin-point to decide the 
identification of specific tissues from their expression profile through the defined 
elements, finally in order to unravel the tissue-specific gene expression in 
determinance of genes or gene clusters, clustering method can be made use of 
68
. 
1.7.1 Creating Tools for cDNA Panel Analysis  
MATLAB
® 
(matrix laboratory) is a high-level language and interactive environment 
for numerical computation and programming. It is possible to analyze data, develop 
algorithms, and create models and applications using MATLAB as a programming 
medium 
69
.  
20 
 
MATLAB provides functions for linear algebra, statistics, filtering, plotting and 
visualization. These features make MATLAB a proper programming medium for 
gene expression analysis. 
With basic mathematical functions raw data of qPCR of a cDNA panel together with 
its covariate information can be processed. For example, means for replicate 
measurements can be taken and ∆Ct or ∆∆Ct values can be calculated by applying 
simple mathematics. Where MATLAB is separated from other programs or tools is 
wide options of statistical analysis it provides; statistical tests include t-test, sign test, 
ANOVA, ANCOVA, Kruskal-Wallis, chi-square, linear and nonlinear regression etc. 
It allows choosing the proper test for data analysis 
69
. 
1.7.2 Outlier Analysis  
In order to check the quality of data, further analyses should be performed. 
Performing the experiments with replicates allows distinguishing the outlier data 
caused by technical or personal mistakes. In real engineering and scientific 
applications, it is widely known that outliers are most probably to be focused 
primarily in every operating step 
70
. One important aspect of qPCR analysis is that 
the reaction should produce a single amplicon with a predetermined and stable Tm 
value obtained upon melt curve analysis. Thus, it is important to detect outliers based 
on Tm values automatically in a cDNA panel for exclusion since these outliers might 
represent different amplification products (e.g., dimers) than the one intended. 
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2. AIM 
Literature search indicated that determining molecular subtypes of breast cancer is 
important in diagnosis. Early diagnosis and therapy of breast cancer is very important 
to increase survival rates.  ER pathway plays role in the development and growth of 
breast cancer. CHRNA5 activity has effects on pathways controlling cell motility, 
proliferation, differentiation and apoptosis 
42
. Our previous studies
49,50
 demonstrated 
that CHRNA5 might be regulated by estrogen 
49 
based on microarray data expression 
analysis and was modulated by estrogen in a time dependent manner. In vivo, ER- 
cells were likely to express more CHRNA5 based on GEO dataset analyses 
49
. 
However, in vivo cDNA panel validation of CHRNA5 expression in association with 
ER status has not been performed yet. 
In this study, our aim is a) to test whether isoform specific CHRNA5 expression 
responds similarly to estrogen exposure in ER positive and ER negative cell lines in 
a dose dependent manner; b) to assess effects of the E2 antagonist tamoxifen and 
long term E2 depletion in MCF7 cells; and c) to investigate isoform specific 
expression profile in vivo for diagnosis of breast cancer. 
Our experimental approaches include testing CHRNA5 isoform expression by qPCR 
in response to different doses of E2 in MCF7 (ER+) and MDA MB 231 (ER-) cell 
lines, and as well as CHRNA5 response to tamoxifen, an inhibitor of estrogen 
response, when given alone or together with estrogen in MCF7 cells. We also 
developed a long term estrogen depletion (LTED) model in MCF7 cells to test 
whether LTED affects ESR1 as well as CHRNA5 isoform expression. We then tested 
whether CHRNA5 expression differs among a set of tumor samples with different 
molecular subtype characteristics using a commercial cDNA panel. We developed 
MATLAB cDNA panel analysis GUI for quality control and statistical analysis of 
qPCR data obtained from OriGene cDNA panels. 
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3. MATERIALS AND METHODS 
3.1 Cell Culture Protocols 
3.1.1 Cell Lines 
For this study, two different cell lines (MCF7, MDA MB 231) were used (ATCC; 
Manassas, USA). They have been cultured in Bilkent University MBG laboratories. 
In order to study the effect of E2, ER- and ER+ cell lines were studied. The origin of 
the cell lines can be found in Table 3.1 
71
. 
Table 3.1: Breast cancer cell lines origin 
Name Source  Tumor Age Ethicity 
MCF7 PE  IDC  69  White 
MDA MB 
231 
PE  AC  51  White 
AC, adenocarcinoma; IDC, invasive ductal carcinoma; PE, pleural effusion. 
The receptor status and molecular subtypes of cell lines are listed in Table 3.2. 
Table 3.2: The receptor status and molecular subtypes of cell lines 
Name ER PR HER2 Molecular 
subtype 
MCF7 + + - Luminal A 
MDA 
MB 231 
- - - Basal 
3.1.2 Cell Growth Conditions 
DMEM (SH30021.01), FBS (SW30160.03), Penicillin/Streptomycin Solution 
(SV30010) and Trypsin/EDTA solution (SH30042.01) were from HyClone (Logan, 
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USA). Non-essential amino acid solution (K0293) (Berlin, Germany) and PBS (17-
516F) (Lonza ,Switzerland) were used to prepare medium. 
The complete growth medium of MCF7 and MDA-MB-231 cells included DMEM 
with 10% Fetal Bovine Serum, 1% Penicillin/Streptomycin solution and 1% Non-
essential amino acids. 
3.1.3 Thawing Cells 
The frozen cell vial obtained from liquid nitrogen was placed in the water bath at 
37°C. After melting, the cells were taken to a 15 ml, sterile tube and total volume 
was adjusted to 5 ml with complete medium. The cells were then centrifuged at 1500 
rpm for 5 minutes; the supernatant was aspirated; the cells were re-suspended in 1 ml 
of complete growth medium and seeded in T25 flasks (Greiner Bio One, 
Frickenhausen, Germany) with 7-8 ml of complete medium. 
3.1.4 Subculturing of Cells 
All cell types were grown in T75 flasks (Grenier Bio One, Frickenhausen, Germany) 
with 12-13 ml of complete medium in an incubator with 5% CO2 at 37°C. When the 
cells reached 80-90% confluency, on average, after 3 days, they were passaged to 
new flasks. For passaging, the old growth medium was aspirated; flasks were washed 
with 5 ml PBS. 1 ml Trypsin/EDTA solution was then added to cover the bottom of 
them for 5-8 minutes in 37°C incubator for detachment of cells, which were then 
collected from flasks using 7-8 ml complete growth medium and centrifuged at 1500 
rpm for 5 minutes. The supernatant was aspirated; the cells were re-suspended in 
complete medium and were seeded into new flasks with the desired dilution 
depending on the amount of pellet and the type of experiment.  
3.1.5 Cryopreservation of Cells 
For cryopreservation, detached cells which were aspirated the old medium washed 
with PBS and trypsinized were centrifuged at 1500 rpm from 5 minutes. Medium 
were aspirated; and pellet was re-suspended in freezing medium (10% DMSO in 
FBS). 1.5-2 ml of this was put into cryotube and stored at -20°C for 1-2 hours, then 
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transferred to - 80°C. For long-term storage the cryotubes should be stored in liquid 
nitrogen. 
3.1.6 Counting Cells with Hemocytometer 
Cells were counted before seeding them for an experiment using hemocytometer.  
Cell pellet obtained after 5 minutes of centrifugation at 1500rpm was completely 
dissolved in 10ml medium; medium was chosen depending on cell type. Then cells 
were diluted 1:10 and 10 µl form this diluted solution was put on hemocytometer. 
Cells from four corners (Figure 3.1.B) of hemocytometer were counted and the total 
number was divided to 4. The division gave the number of how many millions cells 
10ml medium had.  
 
Figure 3.1:  A. Scheme of a whole hemocytometer. B. Right bottom corner of hemocytometer  
3.1.7 β-Estradiol (E2) Treatment 
For β-Estradiol (E2) (E2758; Sigma Aldrich, Missouri,USA) treatment, MCF7 and 
MDA-MB231 cell lines were used. E2 stock solution was prepared by dissolving 
27.238 mg E2 in 50 ml 100% sterile EtOH (32221) (Sigma Aldrich, Missouri, USA) 
so final concentration was 2mM. The stock solution was filtered; aliquoted; and 
stored in -20°C. 
Final E2 treatment concentration were prepared as 1nM, 10nM, and 100nM dilutions 
were made in phenol red-free Dulbecco’s MEM (F0475; Biochrom AG, Berlin, 
Germany) with 5% charcoal/dextran-treated FBS (SH30068.02) (Hyclone, Logan, 
25 
 
USA), 1% penicillin/streptomycin solution and 1% non-essential amino acids. First, 
2mM stock solution was serially diluted as 1:10, 1:100 to obtain 0.2 mM and 
0.02mM E2 solutions, then from each solutions (0.02 mM, 0.2 mM, 2 mM) 1 µl was 
put into 20ml phenol red-free DMEM with 5% charcoal/dextran-treated FBS to 
obtain 1nm, 10nm and 100nm E2 solutions, respectively. 
The medium for E2 control group was prepared by adding 1 µl of 100% EtOH to 20 
ml phenol red-free DMEM with 5% charcoal/dextran-treated FBS, because for all 
doses of E2, same amount of (0.005v/v % EtOH) 100% EtOH was used. 
MCF7 and MDA MB231 were counted and seeded in 8 T75 flasks for each cell line 
at a concentration of 1 x 10
6
 cells/ flask. They were incubated with complete DMEM 
(SW30160.0, HyClone (Logan, USA)) for 24 hours. After 24 hours, the media of the 
cells were changed to phenol red-free DMEM with 5% charcoal dextran-treated FBS 
and incubated for 72 hours. Then, the media then was changed to phenol red-free 
DMEM with 0.1% charcoal/dextran-treated FBS to synchronize cells for 24 hours. 
0.1% FBS medium was aspirated and replaced with 12 ml of dose-specific media 
(Control, 1nM, 10nM,100nM) as explained above was added to the flasks. Each dose 
was performed in duplicates. After 24 hours all treatments were collected. 
3.1.8 Tamoxifen and E2 Treatment 
For tamoxifen (4-OHT) (S1972, Selleck Chem) and E2 treatment MCF7 cell line was 
used. 
2mM E2 stock solution prepared as explained above was diluted 1:10 and 0.5 µl of 
this was added to 10ml phenol red-free DMEM with 5% charcoal/dextran-treated 
FBS to obtain 10nm E2 concentration in medium. 
To obtain 1µM 4-OHT concentration in medium, 1µl from 10mM 4-OHT was added 
in 10ml phenol red-free DMEM with 5% charcoal/dextran-treated FBS. 
The medium for E2 control group was prepared by adding 1 µl of 100% EtOH to 20 
ml phenol red-free DMEM with 5% charcoal/dextran-treated FBS (0.005v/v % 
EtOH), and the medium for 4-OHT control group was prepared by adding 0.5 µl of 
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DMSO to 5 ml (0.01v/v % DMSO) phenol red-free DMEM with 5% 
charcoal/dextran-treated FBS. 
MCF7 breast cancer cells/well were counted and seeded in 8 wells of 2 6-well plate 
as 2x10
5 
cells/well. They were incubated in complete DMEM for 24h. Then same 
procedure with β-Estradiol (E2) treatment has been performed until 6th day of 
seeding.  After 24h synchronization, cells were treated with 1uM 4-OHT+10nm E2, 
10nm E2, 1uM 4-OHT, EtOH and DMSO as duplicated for 24h.  After 24 hours all 
treatments were collected. 
For expression analysis deltadeltaCT (TPT1-Target gene (deltaCt) normalized with 
control) method was used.  4-OHT treated samples were normalized with DMSO, E2 
treated samples were normalized with EtOH and 4-OHT-E2 treated samples were 
normalized with average of DMSO-EtOH. 
3.1.9 Long-term E2 Depletion of Cells 
In order to establish a long-term E2 depletion model, MCF7 cell line was used.  
To prepare depletion and control medium, phenol red-free DMEM with 10% 
charcoal/dextran-treated FBS was used. For control, 2mM E2 stock solution was 
diluted 1/10 to obtain 0.2mM E2 and 2µl from this was added to 40ml phenol red-
free DMEM with 10% charcoal/dextran-treated FBS. For depletion, only 2µl EtOH 
was added in 40ml phenol red-free DMEM (0.005v/v % EtOH) with 10% 
charcoal/dextran-treated FBS. 
For 3 months, MCF7, divided into two flasks after growing in complete DMEM for 2 
days, was cultured in depletion and control medium. Pellets were taken in every three 
days. After 3 months, cells were collected for cryopreservation for 2 months. Then, 
cells 4x10 
6 
were seeded, grown for 3 days, and pellets were collected for 4 weeks. 
There are totally 15 samples from 15 different time points, first three samples belong 
to first month, 4.-6. Samples belong to second month and samples from 7 to 9 are 
from third month, while last five samples belong to sixth month (Table 8.2). 
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3.2 Gene Expression Analyses  
3.2.1 Total RNA Isolation  
Cell pellets taken from flasks should be preserved at -80°C. Before total RNA 
isolation pellets were taken from -80°C and thawed on ice. Then, they were 
completely dissolved in 1ml TRIzol Reagent (15596-026) (Life Technologies, 
California, USA). Dissolved lysates were transferred into 1.5ml tubes and 200µl 
chloroform was added to each tubes. Tubes were shaken vigorously for 15 seconds 
and set for 3 minutes at room temperature. Then tubes were centrifuged at 13.200 
rpm for 17 minutes at 4°C. In this critical step, lysates were separated into three 
phases; the top and clear phase included RNA; this was carefully taken and 
transferred into a new tube. 500µl isopropanol was added to new tubes and tubes 
were gently inverted for 4-5 times. After 10 minutes at RT, they were centrifuged at 
4°C for 12 minutes at 13.200 rpm. The supernatant was carefully removed to 
preserve pellet at the bottom of the tubes, the pellet as washed with 75% EtOH and 
centrifuged at 8.000 rpm for 8 minutes at 4°C. EtOH was discarded; the pellet was 
washed with 100% EtOH and centrifuged at 8.000 rpm for 8 minutes at 4°C. The 
pellet was dried after discarding EtOH; and dissolved in 30-50µl Hypure Molecular 
Biology Grade water (SH30538.03) (Hyclone, Logan, USA). RNA concentration and 
quality were measured with NanoDrop® ND-1000 spectrophotometer (NanoDrop 
Technologies, USA). RNA was stored at -80°C. 
3.2.2 cDNA Synthesis  
Total RNA was used to synthesize cDNA. RevertAid First Strand cDNA Synthesis 
Kit (K1621) (Thermo Fisher Scientific, Massachusetts, USA) was preferred to 
synthesize cDNA. In order to synthesize 1ng cDNA, required volume of RNA was 
calculated and H2O to complete RNA volume to 11µl was added to tubes. 1µl 
oligo(dT) primer was used. Other components were added in this order; 4 µl 5x 
Reaction Buffer, 1 µl RiboLock RNase Inhibitor, 2 µl 10 mM dNTP Mix, 1 µl 
RevertAid M-MuLV Reverse Transcriptase.  The tubes were incubated at 42°C for 
60 min, then 5 minutes at 70°C. They were stored at - 20°C. 
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3.2.3 Oligonucleotides  
Table 3.3 presents the primers used in this study. 
Table 3.3: Primer sequences, their product sizes and efficiencies 
Name Primer sequence (5'-3') 
Size of 
amplicon(bp) 
Amplification 
efficiency 
CHRNA5_v1 
F: AGATGGAACCCTGATGACTATGGT 
R:AAACGTCCATCTGCATTATCAAAC 
104 1.87 
CHRNA5_v2 
F:GGAAACTGAGAGTGGTAGTGGA 
R:CTTCAACAACCTCACGGACA 
122 1.95 
CHRNA5_v3
*
 
F:CATCAGGTGTTGAAGATTGGAAAT 
R:AAAAAGCCCAAGAGATCCAACAAT 
101 1.92 
CHRNA5_iso2
** F:TGGAGAATGGGAGATTGTGAGTGCA 
R:CCAATCTTCAACAACCAGCAACAGC 
78 1.97 
CHRNA5_iso3
** F:TGGAGAATGGGAGATTGTGAGTGCA 
R:CCAATCTTCAACAACGGATACCAGC 
78 1.96 
TPT1 
F:GATCGCGGACGGGTTGT 
R:TTCAGCGGAGGCATTTCC 
100 1.95 
PS2 (TFF1)
*** F:CCATGGAGAACAAGGTGATCTGC 
R:TTAGGATAGAAGCACCAGGGGAC 
208 1.85 
ESR1 
F:AGACATGAGAGCTGCCAACC           
R: GCCAGGCACATTCTAGAAGG 
299 1.78 
FOSL2 
F: GGCCCAGTGTGCAAGATTAGCC 
R: TTTCACCACTACAGCGCCCACC 
 
105 1.99 
 
*(Warzecha et al. 2009) 
** (Falvella et al. 2013) 
***Alotaibi et al. 2006  
CHRNA5 primers used in this study bind the regions showed in Figure 3.2 on exons 
4- 6 of CHRNA5. 
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A
 
B
 
Figure 3.2: Scheme of binding regions of CHRNA5 isoform primers A. Newly designed 
CHRNA5 isoforms used in the experiments on exon 4 – 6 of CHRNA5; CHRNA5_v1_F&R 
detects multiple isoforms while other ones correspond to a transcript that contain a certain part 
of the gene. B. Previously known (Falvella et al. 2013) CHRNA5 isoforms used in the 
experiments on exon 4-6 of CHRNA5 (Only ~150bp of ExonVI was showed in this figure 
1446bp-1596bp).         
3.2.4 Gradient Polymerase Chain Reaction  
Gradient Polymerase chain reaction (gPCR) was performed using OneTaq Quick-
Load Master Mix (M0486L) (New England Biolabs, Massachusetts, USA). New 
primers were tested with this technique using 5 different annealing temperatures (54-
62°C) to see in which Tm primers work best. Gradient PCR reaction was prepared as 
explained in Table 3.4. 
Table 3.4: PCR reagents and their volumes 
 
 
 
 
 
 
 
 
Reagent Volume (µl) 
2x SYBR Green I Master Mix 5 
Forward Primer (10pmol) 1 
Reverse Primer(10pmol) 1 
DNase/RNase-free water 1 
cDNA 2 
Total 10 
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PCR was performed under conditions listed in Table 3.5. 
Table 3.5: PCR conditions 
Step Temperature & Duration 
Initial Denaturation 95°C, 5’ 
Denaturation                                          95°C, 30”                                                                                    
Annealing                                              58°C ∆10, 1.5’         40 cycles 
Extension                                               68°C 1’ 
Final Extension 68°C   10’ 
 
3.2.5 Agarose Gel Electrophoresis  
1.5% agarose gel was prepared with 200ml 1xTAE buffer and 3gr agarose. 1mg/ml 
ethidium bromide solution was added and allowed to polymerase. The wells were 
loaded with 10-12 μl PCR product (for 22 well/gel) or 8-10µl PCR product (for 40 
well/gel). 3 μl GeneRuler 100bp DNA ladder (SM0241) (Thermo Scientific, 
Waltham, Massachusetts, USA) was used as marker. 
3.2.6 Quantitative Real Time-Polymerase Chain Reaction (qPCR)  
Quantitative real time-polymerase chain reactions (qPCR) were performed using 
LightCycler® 480 SYBR Green I Master (04887352001) (Roche Applied Science, 
Germany).  Experiments were performed using every sample as at least duplicates or 
more, including negative controls.  
Plates were LightCycler® 480 Multiwell Plate 96 (04729692001) and (Roche 
Applied Sciences, Germany) PCR machine was LightCycler® 480 PCR Instrument 
(Roche Applied Science, Germany). qPCR reaction was prepared as explained in 
Table 3.6 
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Table 3.6: qPCR reagents and their volumes 
Reagent Volume (µl) 
2x OneTaq QuickLoad Master Mix 12.5 
Forward primer (10pmol) 1 
Reverse primer (10pmol) 1 
cDNA 1 
DNase/RNase-free water 9.5 
Total 25 
 
qPCR was performed under conditions listed in Table 3.7. 
Table 3.7: qPCR conditions 
Step Temperature & Duration 
Initial Denaturation  
 
95°C, 5’ 
Denaturation                                          95°C, 10” 
Annealing                                              58°C, 20”            50 cycles 
Extension                                              72°C, 20” 
 
Acquisition 
 
95°C, 5” 
55°C, 1’ 
95°C, Continuous acquisition 
Final Extension  40°C, 10” 
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3.2.7 Detection of qPCR Outliers Based on Tm Values from Melt Curves 
In order to detect outliers in qPCR data, samples having relatively different melting 
temperature (Tm) values rather than the expected Tm for the primer pairs were 
loaded onto 1.5% agarose gel. 2µl 6x loading dye was added into 10 µl qPCR 
samples and 8µl of samples was loaded into well.  
It was observed that samples having approximately Tm 1°C smaller or l°C larger 
than expected Tm (detected by taking median of all Tm values in the cDNA panel) 
generally provided bands with different sizes than the expected PCR product sizes. 
They were characterized as primer dimers, DNA contaminations or different 
dimerization products. To increase the reliability of data, samples having ±1 different 
Tm than regular Tm were removed and was not included in future analyses.  
3.2.8 Primer Efficiency 
Primers should be tested before using them in order to be sure of their amplification 
efficiencies. It is important to obtain reliable results in every experiment for which 
the primers are used. Optimizing the conditions which primers work best under and 
calculating efficiency of primers are needed to be sure of the quality of primers and 
trustworthiness results. 
Primer efficiencies for each pair of primers were calculated to 1/5 fold dilution series 
and for each gene it was repeated at least once before taking the average efficiency 
value. Perfect PCR efficiency should demonstrate a change of 2.3 cycles between 5 
fold dilutions of the template. 
Primer amplification efficiencies listed in Table 3.2 were obtained by tested primers 
with serially diluted cDNA. Two cDNA pools obtained from MDA MB 231, MCF7, 
HCC1937, BT20, and MCF7; and MDA MB 231, MCF7, MDA MB 361, BT20 and 
MDA MB 468 cell lines serially diluted as 1:5, 1:25, 1:125 and 1:625. Listed primers 
were tested using these four dilutions in a regular qPCR reaction described in Table 
3.4.  
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Threshold cycle (Ct) values and logarithm of dilutions were plotted; the efficiency 
was calculated with this formula; 
E= 10^(-1/m) 
Where, E is primer efficiency and m is the slope of Ct-log(dilutions) graph. 
3.2.9 ∆Ct and ∆∆Ct Analysis of qPCR Data 
In order to determine the relative quantification of a target gene in comparison to a 
reference gene ∆Ct and ∆∆Ct values depending on primer efficiencies were 
calculated.  
For E2, 4-OHT and LTED experiments, after taking mean of Ct value for duplicates, 
∆∆Ct values were calculated using the formula; 
∆∆Ct =(Etarget
ΔCt(target)
/Eref
ΔCt(ref)
) 
log2(∆∆Ct) 
 
E is primer efficiency,  
ΔCt(target) is control target-treatment target  
ΔCt(ref) is control ref-treatment ref 
In this analysis method, a relative quantification based on relative expression of a 
target gene versus reference gene can be obtained to investigate the physiological 
changes in gene expression
64,65
. 
For cDNA panel experiments, efficiency corrected ∆Ct values, as defined here 
correspond to -∆Ct considering the direction of Ct values, were calculated using this 
formula; 
∆Ct= log2(Eref 
Ct(ref)/
Etarget 
Ct(target)
 ) 
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3.2.10 ANOVA analysis 
ANOVA test was used in analysis of each qPCR experiment in order to test the 
significance of the data. After taking data and checking the Tm as described, an excel 
file was created including data and the groups wanted to be analyzed. Each treatment 
or each cell line was labeled to introduce them into ANOVA test. 
General function construct used in the analysis of this study was 
[P,ANOVATAB,STATS] = ANOVA1(X, GROUP) 
Where ANOVA1performs a one-way ANOVA for comparing the means of two or 
more groups of data, it returns the p-value (P) for the null hypothesis that the means 
of the group means are equal. Multiple test corrections were performed using 
multcompare function in MATLAB. Two different multcompare methods were used, 
the ‘hsd’ option stands for ‘honestly significant difference’. The ‘lsd’option stands 
for ‘least significant difference’ and uses plain t-test, it provides no protection against 
multiple comparison problems. 
3.3 Analysis of E2 Treatment  
In order to clearly present E2 treatment data, efficiency corrected log2(∆∆Ct) values 
were used in clustering and drawing heatmap. Similarly, ∆Ct values were used also 
in the clustering to show the differences (before normalization with control group) in 
PS2, an E2 responsive gene, between ER+ and ER- cell lines. 
3.3.1 Clustering 
Cluster 3.0 
72
 program was used to cluster ∆∆Ct values of E2 treatment experiment. 
Euclidean distance was used while clustering average linkage of data. 
3.3.2 Treeview analysis 
TreeView program was used to draw heatmap using clustering data obtained from 
Cluster 3.0. High-expression was represented with red color while green was chosen 
for low-expression (down-regulation).  
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3.4 Analysis of 4-OHT and E2 Treatment 
In order to clearly present E2 treatment data, efficiency corrected log 2(∆∆Ct) values 
were graphed using GraphPad Prism 6 program. Five genes and data belonging to 
their expressions under E2+4-OHT, 4-OHT, E2 treatment and control were plotted 
using GraphPad. Grouped graphic type was chosen to be able show data belonging to 
same gene in the same cluster. Gene names were placed on x-axes, mean of set1 and 
set2 for each treatment group was taken by GraphPad and error bars showing 
standart deviation were added to y-axes.   
3.5 Analysis of Long-term Estrogen Depletion Experiment 
In order to clearly present LTED data, efficiency corrected ∆∆Ct values were 
graphed using GraphPad Prism 5 program and sign test was applied to see whether 
there is a consistent increasing or decreasing positive or negative trend after LTED .  
∆∆Ct values (treatment (T) value was paired with its control (C) at a specific time 
point) were calculated and they were plotted for each time point. This graph type was 
chosen to see how the difference between C and T groups changed throughout six 
months. Sign test was applied the C-T values for each gene using p=signtest(x) 
command in Matlab; x is an array containing C-T values.  
3.5 Analysis of cDNA Panel 
Breast Cancer cDNA Array II (BCRT101) (OriGene, Rockville,USA) consists of 48 
different breast cDNA, 7 of them are normal and remaining 41 are cDNAs obtained 
from breast tumor tissues [Breast cancer cDNA Array II SKU# BCRT501]. The 
datasheet of panel provides information about gender, age, ethnicity, ER, PR and 
HER2 status, grade, stage, pathology of samples (Table 8.1). While the detailed 
information provides an opportunity to evaluate data from different aspects, 
analyzing data becomes more complex and requires automation; however, there is no 
free software or GUI that enables that for ORIGINE cDNA panels. Therefore, 
functions to extract, normalize, perform Tm check, and statistically analyze and plot 
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the cDNA qPCR data for target genes were written in MATLAB in a user friendly 
GUI.   
3.5.1 Statistical Analysis of qPCR Data 
In order to test the significance of results obtained from cDNA panels mainly 
ANOVA test was performed using efficiency corrected log2(∆Ct). Efficiency 
corrected ∆Ct= Eff ^(reference Ct )/Eff ^(target Ct). 
Also correlation between isoform of CHRNA5 for cancer samples was plotted to see 
if isoforms behave in same way under same conditions.  Finally in order to make the 
codes more sophisticated and user friendly a GUI application was designed allowing 
to user choose data, correct, and publish them (please see Results).  
3.5.1.1 Correlation Analysis 
Each gene tested in cDNA panel plotted against each other to see whether they were 
correlated or not, plots were categorized according their receptor status and stages. 
Each group in a category was plotted using different color scale. i.e in ER status plot 
ER- and ER+ samples  were labeled using different colors. This allows seeing how 
genes were clustering according to receptor status and stages.  
3.5.1.2 MATLAB GUI Application  
The MATLAB codes for this application are available and the process has been 
shown in the Results section. 
3.6 General Solutions 
• 50x Tris-acetic-EDTA (TAE): 242 g Tris base and 18.6 g EDTA were dissolved 
in ddH2O. 57.1 ml glacial acetic acid was added and the volume was completed to 1 
lt. pH was set to 8.0. 
• 6X DNA Loading Dye: 10mM Tris-HCl (pH 7.6), 0.03% bromophenol blue, 
0.03% xylene cyanol, 60% glycerol, 60mM EDTA (0.5M pH8.0) 
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• Ethidium Bromide: 10 mg/ml dissolved in ddH2O (stock) 1:10.000 working 
dilution (1µl per 10ml of gel)  
  
38 
 
4.RESULTS 
4.1 Effects of Different Doses of E2 on CHRNA5 Isoform Expression 
4.1.1 Preliminary PCR for MCF7 and MDA-MB-231 Treated with Different 
Doses of Estradiol (E2) 
After the E2 treatment treated cDNAs obtained from RNA of treated cells were 
tested with CHRNA5_iso2 primer by regular PCR. The aim was to see whether 
expression difference between E2 doses can be recognized with regular PCR with 35 
cycles. 
Figure 4.1 shows the results of PCR such that, a slight increase can be seen with 
increasing doses. However, the agarose gel image is not enough to judge the effects 
of E2 on expression of the gene showing importance of qPCR for detection of 
quantitative changes in gene expression. 
 
Figure 4.1:  Representative expression of CHRNA_iso2 products across ER-and ER+ breast 
cancer cell lines treated with 1nm, 10nm and 100nm E2. C indicates the control groups. Each 
dose has a biological duplicate. The arrow indicates the expected amplicon size which is 93bp. 
4.1.2 Statistical Analysis of E2 Treatment with MATLAB 
In order to decide the statistical significance of expression changes in CHRNA5 
isoforms after E2 treatment between different doses of treatment, ANOVA was used 
and calculations were performed in MATLAB. 
First the mean expression difference between different doses and cell lines were 
tested with two-way ANOVA analysis. ER+ MCF7 and ER- MDA MB 231 under 
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treatment of E2 were tested to see how different ER+ and ER- cell lines behave upon 
exposure to E2 treatment (Table 4.1, top). 
Table 4.1: p-values of each gene comparing MCF7 and MDA MB 231 cell lines and different 
doses of E2 based on two-way and one-way ANOVA   
 ∆∆Ct ∆Ct 
Genes p-values (Cell 
line) 
p-values 
(Doses) 
p-values  
(Cell line) 
CHRNA5_v2 0.0006 0.085 0.8484 
CHRNA5_v3 0.0075 0.5849 0.122 
CHRNA5_iso2 0.0027 0 0.3525 
CHRNA5_iso3 0.0052 0.009 0.4642 
PS2 0.0063 0.002 0 
 
 v2 v3 iso2 iso3 PS2 
p-value 0.001 0.0478 0.0002 0.0098 0.0054 
Mult 
compare 
M C-M 10nm 
M C-M 100nm 
M 1nm- MD 1nm 
M 10nm- MD C 
M 10nm- MD 1nm 
M 10nm-MD 10nm 
M 10nm- MD 100nm 
M 100nm- MD C 
M 100nm- MD 1nm 
M 100nm- MD 10nm 
M 100nm-MD 100nm 
 M C-M 1nm 
M C-M 10nm 
M C-M 100nm 
M C-MD 10nm 
M C-MD 100nm 
M 1nm- MD C 
M 10nm- MD C 
M 10nm- MD 1nm 
M 100nm- MD C 
M 100nm-MD 1nm 
MD C- MD 10nm 
MD C-MD 100 
 
M C-M 1nm 
M C-M 100nm 
M 10nm- MD C 
M 100nm- MD C 
 
 
 
 
M C-M 10nm 
M C-M 100nm 
M 10nm- MD C 
M 100nm- MD C 
 
 
 
The results demonstrated  that each CHRNA5 iso2 and iso3 isoforms and PS2 
(TFF1), an E2 responsive gene, showed significantly different expression under 
different doses of E2 treatment; moreover effect of E2 treatment differed 
significantly from cell line to cell line for all genes tested at p<0.05 or less. While 
∆∆Ct shows the fold change of expression, ∆Ct implies absolute values of 
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expression; that is why only PS2 expression shows highly significant expression 
difference between ER- and ER+ cell lines based on deltaCt Two-Way-ANOVA 
(Table 4.1). 
Analyzing MCF7 and MDA MB 231 data together by One-Way-ANOVA gave us 
the opportunity to increase sample size and multiple test comparisons showed 
differences between cell lines and between doses (Table 4.1, bottom). After showing 
the expression level difference between ER+ and ER- cell lines as in Table 4.1, each 
of the cell lines were analyzed one by one to see the effect of different E2 doses on 
CHRNA5 isoform expression level using One-Way ANOVA and multcompare in 
MATLAB (Tables 4.2-4.5). 
Accordingly, MCF7 cell line which is ER+, was generally more affected by E2 
treatments than ER- cell line MDA-MB-231 (Figure 4.2). 
41 
 
CHRNA5_v2
Control 1nm 10nm 100nm
-2
0
2
4
Dose (nm)
E
x
p
re
s
s
io
n
 l
e
v
e
l 
(l
o
g
)
CHRNA5_v3
Control 1nm 10nm 100nm
-2
0
2
4
Dose (nm)
E
x
p
re
s
s
io
n
 l
e
v
e
l 
(l
o
g
)
CHRNA5_iso2
Control 1nm 10nm 100nm
-2
0
2
4
Dose (nm)
E
x
p
re
s
s
io
n
 l
e
v
e
l 
(l
o
g
)
CHRNA5_iso3
Control 1nm 10nm 100nm
-2
0
2
4
Dose (nm)
E
x
p
re
s
s
io
n
 l
e
v
e
l 
(l
o
g
)
PS2
Control 1nm 10nm 100nm
-2
0
2
4
Dose (nm)
E
x
p
re
s
s
io
n
 l
e
v
e
l 
(l
o
g
)
Figure 4.2: Effects of E2 doses on CHRNA5 isoforms and PS2 in MCF7 cell line (∆∆Ct). Lines 
above the graphs indicate the group having statistically different expression using lsd (t-test 
equivalent) method. 
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CHRNA5_v2 and CHRNA5_iso2 was directly affected by increases in E2 doses, 
however CHRNA5_v3 did not follow that kind of trend by showing a higher 
expression under 10nm E2 treatment than 100nm E2 treatment. CHRNA5_iso3 
reached saturation after 10nm dose and did not show any difference in expression 
level even after 100nm E2 treatment. PS2 is known a responsive gene to E2 
treatment, so it was used as control for E2 and despite closeness of PS2 expression 
levels in 1nm and 10nm E2 treatments, an increase with rising E2 doses can be 
observed in PS2 expression. p-values for each group can be seen in Table 4.2. 
Table 4.2: p-values of each gene comparing E2 doses in MCF7 cell line from ANOVA test 
Genes p-values 
CHRNA5_v2 0.055 
CHRNA5_v3 0.3794 
CHRNA5_iso2 0.0011 
CHRNA5_iso3 0.0592 
PS2 0.0675 
Average of CHRNA5 
isoforms 
0.0277 
 
Multiple comparisons between each group were performed with and without 
correction against the multiple comparison problem and groups giving significant 
results were listed in Table 4.3. 
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Table 4.3: List of group having statistically significant expression difference for each gene 
Multcompare 
type 
Genes Groups with significant 
expression difference 
With 
correction (hsd) 
CHRNA5_iso2 Control-1nm,Control-
10nm,Control-100nm 
 Ave. of CHRNA5 
isoforms 
Control-10nm, Control-100nm 
Without 
correction (lsd) 
CHRNA5_v2 Control-10nm, Control-100nm 
CHRNA5_iso2 Control-1nm, Control-10nm, 
Control-100nm 
CHRNA5_iso3 Control-10nm, control-100nm 
PS2 Control-1nm, Control-10nm, 
Control-100nm 
Ave. of CHRNA5 
isoforms 
Control-1nm, Control-10nm, 
Control-100nm 
 
CHRNA5_iso2 showed highly significant expression difference depending on E2 
doses while the others had test statistics approaching significance (<0.06) except 
CHRNA5_v3. However, ANOVA may cause the loss of significance because of low 
sample size; therefore a multiple comparison without correction (raw t-test values) 
was applied, too. It was seen that almost all doses significantly affect CHRNA5 gene 
expression except in v3 (Table 4.3). Also average of CHRNA5 isoforms were 
calculated and ANOVA was applied to obtain a generic idea about CHRNA5 
expression-E2 treatment relationship and it was seen CHRNA5 expression was 
affected significantly (Table 4.2, Table 4.3). 
Effects of different doses of E2 on MDA MB 231 cell line was also tested with 
ANOVA test and plotted (Figure 4.3). 
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Figure 4.3: Effects of E2 doses on CHRNA5 isoforms and PS2 in MDA MB 231 cell line (∆∆CT). 
Lines above the graphs indicate the group having statistically different expression using lsd (t-
test equivalent) method. 
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Any of the tested genes in MDA MB 231 cell line did not show a regular expression 
trend in a dose dependent manner although some isoforms exhibited increasing or 
decreasing expression across treatments (Figure 4.3). According to ANOVA 
comparing control and each dose of E2 in MDA MB 231 cell line, CHRNA5_v3, 
CHRNA5_iso2 and PS2 expression have significantly changed (Table 4.4) but 
CHRNA5_v3 was downregulated while CHRNA5_iso2 and PS2 were upregulated 
(Figure 4.3). The observation that CHRNA5_v2 and CHRNA5_v3 isoforms 
exhibited dose dependent decreases in response to E2 in MDA-MB-231 and an 
increase in MCF7 showed that it was important to analyze isoform specificity in 
response to E2. On the other hand iso2 was positively affected by E2 in both cell 
lines based on ANOVA analyses followed by pairwise comparisons (Tables 4,4 and 
4.5).  
Table 4.4: p-values of each gene comparing E2 doses in MDA MB 231 cell line from ANOVA 
test 
Genes p-values 
CHRNA5_v2 0.0783 
CHRNA5_v3 0.0509 
CHRNA5_iso2 0.0378 
CHRNA5_iso3 0.2702 
PS2 0.0082 
Average of CHRNA5 isoforms 0.3691 
 
When the average of CHRNA5 isoforms was taken ANOVA was not significant for 
ER- MDA MB 231 (Table 4.4). This indicates that there could be isoform specific 
differences in response of CHRNA5 to E2 in ER- cell line MDA-MB-231 but not in 
ER+ MCF7 cells. 
Multiple comparisons between each group were performed and groups giving 
significant results were listed in Table 4.5. PS2 shows statistically significant 
expression change between high doses of E2 treatment. 
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Table 4.5: List of group having statistically significant expression difference for each gene 
Multcompare type Genes Groups with significant 
expression difference 
With correction (hsd) 
CHRNA5_iso2 Control-10nm,Control-
100nm 
PS2 Control-100nm, 10nm-
100nm 
Without correction 
(lsd) 
CHRNA5_v2 Control-1nm, 1nm-100nm 
CHRNA5_v3 Control-1nm, Control-10nm 
CHRNA5_iso2 Control-1nm, Control-
10nm, Control-100nm 
PS2 Control-1nm, Control-
100nm, 1nm-100nm, 10nm-
100nm 
4.1.3 Heat Map of CHRNA5 Isoform and E2 Markers Expression 
Heatmap graphs provide opportunity to visualize a coordinated expression data set 
from multiple genes at once. Both expression of each cell line and the difference 
under treatment of each dose can be observed in a single graph.  
Also reliability of experiment data can be clearly interpreted because of clustering of 
data. Heatmap showed that treatment group clustered together in a cell line-specific 
manner (Figure 4.4).  
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Figure 4.4: Heatmap representations of expression level of CHRNA5 isoforms and PS2 in MCF7 
and MDA MB 231 cell lines. Red indicates an increase in expression and green indicates a 
decline. Euclidian distance was used as distance method and average linkage was taken for 
clustering. Map on the right side was obtained from ∆∆Ct analysis and the one at the left side 
was from ∆Ct analysis. 
Heatmap graphs clearly showed that expression responses of MCF7 and MDA MB 
231 to E2 treatment were different as they clustered in separate groups. Also in each 
cluster E2 doses were almost ordered, showing that genes were affected by changes 
in E2 doses. Moreover, genes in MCF7 cell line were highly upregulated with E2 
treatment when compared with controls, while MDA MB 231 cells both have up- 
and downregulated genes but the magnitude of change was relatively less when 
compared with MCF7 (Figure 4.4, left side). On the other hand ∆Ct analysis derived 
heat map (Figure 4.4, right side) showed that PS2 could strictly distinguish ER- and 
ER+ cell lines.  
For further analysis of E2 treatment data, regression and/or ANCOVA (testing slope 
difference for both cell lines at the same time) can be used to predict how CHRNA5 
expression changes depending on different doses of E2. Moveover, other statistical 
tests appropriate for analysis of gene expression datasets with small sample sizes can 
be applied for testing differences between groups within and between cell lines, e.g., 
limma 
73
. 
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4.2 Effects of 4-OHT and E2 Treatment 
4-OHT (generally known as tamoxifen) is an ER antagonist which prevents E2 from 
binding to ER. Considering E2 and ER pathway trigger proliferation, 4-OHT should 
decrease the effect of E2 by blocking ER pathway, in particular for tamoxifen 
sensitive cells. The effects of E2 and 4-OHT treatment (both individually and 
together) were examined on CHRNA5 isoforms expression as well as selected E2 
and 4-OHT marker genes for making comparisons.  
4.2.1 Statistical Analysis of 4-OHT and E2 Treatment with MATLAB 
ANOVA was used to test significance between the expression differences of genes 
(CHRNA5 isoforms as well as PS/TFF1 and FOSL2) under E2, 4-OHT, E2+4-OHT 
treatment. PS2 gene expression has been a well known marker of E2 response and 
thus was used to assess the effectiveness of E2 
74
. Our preliminary analysis of the 
GEO dataset (GSE26459) also has led to identification of FOSL2 as a potential 
responder to 4-OHT and E2 application (Appendix; Figure 8.1 and 8.6). In tamoxifen 
sensitive cell lines it is expected that FOSL2 expression level might increase after 
E2+4-OHT treatment up to two-fold  
75
 (Figure 8.1).  In case of resistance to 4-OHT, 
however, both E2 or E2+4-OHT treatment can increase FOSL2 expression up to 
three fold while no change from control is expected for 4-OHT alone (Figure 8.6). 
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Figure 4.5: Effects of E2 and 4-OHT on CHRNA5 isoforms, E2 and 4-OHT indicators in MCF7 
cell line 
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The results demonstrated that 4-OHT had significant effects on CHRNA5 isoform 
expression as well as PS2 (Figure 4.5; Table 4.6). Multiple comparisons indicated 
that the difference between E2 and tamoxifen was significant for CHRNA5_v1, v3, 
iso3 and PS2 genes (Table 4.6). For PS2 all groups were significantly different from 
each other while for v1, control and tamoxifen showed difference together with E2 
and tamoxifen. For the other two genes only E2 and tamoxifen showed difference.  If 
E2 has increased CHRNA5 expression and tamoxifen decreased it we would expect 
to see that when tamoxifen given together with E2 also should decrease (when 
compared with E2) the expression of CHRNA5, or any other E2 responsive gene. If 
we look at PS2, a known E2 responsive gene, the effect of E2 (compared with 
control) caused upregulation with and without 4-OHT. FOSL2 shows a similar 
expression pattern with the previous research however the changes were not 
significant 
75
. This could be because the dose of E2 (10nM) overrides the effect of 
1uM tamoxifen, i.e., the neutralization of E2 effect by tamoxifen could be dose-
dependent. Another possibility could be that sensitivity of MCF7 to tamoxifen might 
vary from passage to passage or batch to batch in MCF7 cells. Interestingly, 
CHRNA5_v1 and CHRNA5_v2 expression drastically decreased with 4-OHT 
treatment however E2 did not seem to be effective for these genes in this experiment. 
However, CHRNA5_iso2 and CHRNA5_iso3 expressions changed as expected. 
Although CHRNA5_v3 shows an increase in expression after E2 treatment, this was 
not enough to revert its expression after co-treatment with 4-OHT (Table 4.6).  
These results suggest that for most of the genes we studied at least one group’s mean 
expression was different from one or more. To see which groups were significantly 
different from each other we performed multiple test comparisons using 
multcompare (Table 4.7). 
Table 4.6: p-values of each gene comparing control, E2, 4-OHT, and E2 and 4-OHT together in 
MCF7 cell line from ANOVA test 
Genes p-values 
PS2 0.0058 
CHRNA5_v1 0.0291 
CHRNA5_v2 0.0633 
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CHRNA5_v3 0.0497 
CHRNA5_iso3 0.0438 
CHRNA5_iso2 0.075 
FOSL2 0.1321 
 
Table 4.7: List of group having statistically significant expression difference for each gene 
Genes Groups with significant 
expression difference with 
correction 
Groups with significant 
expression difference 
without correction 
PS2 Cont-4-OHT,E2-4-OHT, 4-
OHT-E2+4-OHT 
Cont-4-OHT,E2-4-OHT, 
4-OHT-E2+4-OHT 
CHRNA5_v1 Cont-4-OHT,E2-4-OHT Cont-4-OHT,E2-4-OHT, 
4-OHT-E2+4-OHT 
CHRNA5_v2 - Cont-4-OHT,E2-4-OHT, 
4-OHT-E2+4-OHT 
CHRNA5_v3 E2-4-OHT Cont-4-OHT,E2-4-OHT 
CHRNA5_iso2 - E2-4-OHT, 4-OHT-
E2+4-OHT 
CHRNA5_iso3 E2-4-OHT 
E2-4-OHT, 4-OHT-
E2+4-OHT 
 
4.2.2 Comparison of CHRNA5 Isoform and E2 and 4-OHT Markers Expression  
A comparative histogram showing all isoforms also was drawn below (Figure 4.6). It 
was seen that CHRNA5_v3 was relatively sensitive to tamoxifen and when given 
together with E2 it reduced the expression level. 
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Figure 4.6: Overall representation of expression level of CHRNA5 isoforms and E2, 4-OHT 
indicators. 
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4.3 Effects of Long-term E2 Depletion (LTED) on CHRNA5 Isoform 
Expression 
To address the mechanism behind the relationship between E2 depletion - CHRNA5 
in breast cancer we generated an isogenic cell line of MCF7 that has gone through 
long-term E2 depletion. It is thought that the response of breast cancer line may 
differ after a short period of E2 depletion than long term of E2 depletion in gene 
expression level 
36
.  
During a period of six months, E2 depleted and normal (where E2 was manually 
added into growth medium) MCF7 cell lines were cultured. The time points belong 
to each samples can be seen in table 8.7. Expression of CHRNA5 isoforms and 
estrogen signaling pathway markers (PS2 and ESR1) were studied by qPCR. Results 
were analyzed using paired tests across this time series qPCR data in MATLAB.  
4.3.1 Determining the Housekeeping Gene for LTED Experiment 
It is important to find a reliable housekeeping gene not affected by the lack of E2 in 
the cell line experiments. In this study, TPT1 gene was chosen as housekeeping gene 
and its expression was measured over six months.   
To determine whether TPT1 gene is a consistent and reliable housekeeping gene 
difference between control and treatment (depletion) group per time was plotted 
(Figure 4.7). Also sign test result showed that there was no significant positive or 
negative collection of values in TPT1 expression throughout six months (Table 4.8). 
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Figure 4.7:  Changes in gene expression of treatment with respect to control of TPT1 expression 
per time point during six months of E2 depletion with ∆∆Ct analysis. Arrow indicates the end of 
third month.  
 
Except one time point the expression of TPT1 gene did not differ between the control 
(with E2) and treatment (without E2) group during six months. This plot indicated 
that TPT1 could be a reliable housekeeping gene that can be used in further analysis. 
4.3.2 Expression of CHRNA5 Isoform and E2 Exposure Markers across LTED 
During the first three months of experiment, cells were cultured and split without 
counting and without considering time (hr) of the pellet collection. This might cause 
a fluctuation in gene expression especially if the data is analyzed in an unpaired 
fashion. Thus we have analyzed the expression difference between treatment (T) and 
control (C) groups per time point when normalized with respective TPT1 values 
(∆∆Ct) (Figure 4.8-4.9). 
During 6
th
 month of exposure, to increase consistency and reliability of data across 
time points all cells were seeded in a predetermined number after counting, and also 
they were cultured at the same time of the day in order not to interfere with the cell 
cycle. It is important to note that at later time points the difference between control 
and treatment groups stabilized compared to earlier timer points also in response to 
the effects of LTED. 
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Figure 4.8: Changes in gene expression of treatment with respect to control of CHRNA5 
isoforms expression per time point during six months of E2 depletion with ∆∆Ct analysis. Arrow 
indicates the end of third month. 
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Figure 4.9: Changes in gene expression of treatment with respect to control of E2 indicators 
expression per time point during six months of E2 depletion with ∆∆Ct analysis. Arrow 
indicates the end of third month. 
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The most striking result we obtained from LTED experiment was that ESR1 
expression was significantly different after fifth time point onwards corresponding to 
the middle of second month between  C (control) and T (E2 depleted) groups. ESR1 
expression in second month (4-6. points) comparing to first month (1-3. points) 
highly increased by LTED, and despite the fluctuation, CHRNA5_v2 and 
CHRNA5_v3 also showed upregulation throughout these three months. PS2 did not 
follow any trend; its expression without E2 first was smaller than control then 
became larger than the control. After time point 10 (beginning of sixth month) the 
PS2 expression without E2 became reduced in amount when compared with the 
control (Figure 4.9). 
Last five samples covering sixth months had less variation within groups than first 
three months.  Despite PS2 showed a decreasing trend towards the end of the sixth 
month, the expression level of PS2 could still be considered high in Treatment versus 
Control when comparing with the samples belonging to initiation of the study (first 
weeks). CHRNA5_v2 and in particular CHRNA_v3 did not show much fluctuation 
yet they had an increasing trend. In GEODataSet results for PS2, the expression 
decreases first month then it increases at the third month and remains at the same 
level at sixth month (Figure 8.4).  
Table 4.8 shows the result of sign test applied for each gene to see whether there is a 
positive or negative trend between the differences in expression of control and 
treatment group in LTED.  
Table 4.8: p-values of each gene comparing expression after six months of estrogen depletion 
from sign test 
 CHRNA5_v2 CHRNA5_v3 ESR1 PS2 TPT1 
p-value 0.7905 0.0018 0.0129 0.1796 0.7905 
 
In this analysis, p-value showed how the samples were different from their median or 
whether they increased or decreased consistently. Table 4.10 indicates that PS2 and 
CHRNA5_v2 do not regularly decrease or increase; however ESR1 and 
CHRNA5_v3 showed a significant difference between LTED and its control across 
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time points. We generated a promising model to test the effects of LTED on isoform 
specific gene expression including CHRNA5 isoforms.  
4.4 Expression of CHRNA5 Isoforms in cDNA Panel 
In order to study how different isoforms of CHRNA5 gene are expressed in different 
subtypes of breast cancer a cDNA panel from ORIGENE was examined. CHRNA5 
expression difference between normal and tumor breast tissues as well as differences 
among tumor samples with different receptor status were compared in terms of 
CHRNA5 isoform expression upon normalization with TPT1 as the reference gene.  
ANOVA test was mainly used because of large sample size. To study the correlation 
between isoforms and their ability to separate based on receptor status and stage 
Pearson correlation coefficients and scatter plots were used. Efficiency corrected ∆Ct 
method was used for analyses. Multiple cDNA panels, each with two technical 
replicates for each well were studied with 1/20 dilution with a negative control; and 
only non-contaminated runs for each primer were used. Replicates were averaged for 
each sample before statistical analyses. 
4.4.1 Data Quality Control Studies 
The data coming as a result of qPCR procedure may be problematic in several ways 
especially for genes expressed at low levels. First of all, a well can be read as empty 
while its duplicate  gives a reliable Ct value; second, there may be relatively large Ct 
differences between duplicates; and third, Tm values may vary among duplicates 
and/or samples tests. Pipetting errors, technical problems during sample preparation 
as well as performing the reaction in a qPCR machine can also contribute to 
variability obtained between duplicate measurements or gathering of the qPCR data 
from studies that use large plates (96 well or 384 well). Therefore it is important to 
assess the quality of the qPCR data in terms of different quality checks for duplicate 
variability as well as Tm and amplicon size differences. 
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4.4.1.1 Tm Consistency Check in cDNA Panels 
To be sure of the accuracy of Ct values we checked the consistency of Tm values for 
a primer pair in a run. A reliable primer should work with similar and relatively close 
Tm’s under similar conditions when the experiment is repeated. However, we don’t 
know how much variation in the Tm values should be tolerated  If Tm values of 
some wells in qPCR plate are unexpectedly deviant than others, the Ct values of 
these wells may not belong to tested primer, or double Tm measurements may refer 
to dimer formation or other artifactual hybridization between strands.  
In order to label a Tm value as deviant or marginal a threshold should be determined. 
The threshold was determined by examining qPCR products with different Tm 
values. Median of all Tm values in the cDNA panel was taken, then samples less or 
more than one degree Centigrade different from this median were loaded into 
agarose gel together with positive controls. In Figure 4.10, a representation of this 
study can be seen. 
 
Figure 4.10: Gel image of qPCR products from different experiment with varying Tm values. 
Thin arrow indicates qPCR product having closer Tm with the median, it was loaded as control. 
Normal Tm expectancy for this primer was 81.11 ⁰C. Bold arrow indicates expected amplicon 
size, which is 93bp. 
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Figure 4.11: Representative melting curve. Tm curves having different Tm than the median 
differ from each other. 
After examining gel images, we estimated that qPCR products with Tm values ± 
1degree were likely to be different than that of positive control and did not give 
bands at the same size with the control. These were generally dimers, sometimes 
heteroduplexes, artifacts, or smear.  
As a result of this strategy, it was decided to remove samples with Tm values ± 
different than that of control and samples with double Tm values before any further 
analysis. 
  
Figure 4.12: Representation of Ct value distribution before and after Tm outlier removal. First 
figure belongs to the data before Tm checks and exclusion and second one is boxplot of the same 
data after exclusion of wells with inconsistent Tms. The variation considerably decreased after 
Tm outlier removal. 
4.4.2 Statistical Analysis of CHRNA5 Isoforms Expression 
The level of changes in the CHRNA5 isoform level in breast tumor samples 
compared to normal breast tissue as well as to the receptor status and CHRNA5 
isoforms expression (v1-v3) were studied.  
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One-way ANOVA was performed for each gene after normalizing their Ct value 
with housekeeping TPT1 gene with efficiency correction. p-values were obtained to 
compare normal-tumor, ER+ - ER-, HER2+ - HER2- and stages of tumor. Table 4.9 
shows p-values derived from ANOVA test. 
Table 4.9: p-values of each CHRNA5 isoform normal-tumor, ER+ - ER-, HER2+ - HER2- and 
stages of tumor in cDNA panel 
p-values Normal-
Tumor 
Normal-ER+,  
ER- 
Normal-
HER2+, 
HER2- 
Normal-
Stages 
CHRNA5_v1 0.0076 0.0072 0.0174 0.014 
CHRNA5_v2 0.0031 0.0097 0.0162 0.0013 
CHRNA5_v3 0.0249 0.0003 0.083 0.0109 
Ave. of three 
isoforms 
0.0055 0.0022 0.0188 0.0035 
Table 4.10 represents the result of multiple comparison test performed to see p-
values are significant between exactly which groups. 
Table 4.10: List of group having statistically significant expression difference for each gene 
Multcompare Normal-ER+,  ER- Normal-HER2+, 
HER2- 
Normal-Stages 
CHRNA5_v1 N-ER-, N-ER+ N-HER2+ II-N 
CHRNA5_v2 N-ER- N-HER2-, N-HER2+ II-N, III-N 
CHRNA5_v3 ER+ - ER-, N-ER- - II-N 
Ave. of three 
isoforms 
N-ER-, N-ER+ N-HER2-, N-HER2+ II-N 
 
According to results of ANOVA, expression of each isoform of CHRNA5 
significantly differed between normal and breast tumor tissue, a finding supporting 
previous studies on CHRNA5 isoforms in lung cancer 
44
.  CHRNA5_v2 showed the 
most drastic change with a p-value equal to 0.0031 (Table 4.9).   
After interpreting p-values and multiple comparison results, it seems that even 
CHRNA5_v1 expression significantly differs between tumor and normal breast 
tissue although this isoform was not enough to distinguish subtypes of breast cancer; 
i.e.., ER+ and ER- samples did not show any remarkable difference according to 
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multiple comparison results.  However, stage II seems to be distinguished from 
Normals when analyzing CHRNA5_v1 expression (Table 4.10).  
CHRNA5_v2 followed a similar trend with CHRNA5_v1 except its expression more 
remarkably differs according the p-values. Also, CHRNA5_v2 provides opportunity 
to differentiate stage III as well as stage II from normal tissue.  
CHRNA5_v3 was not effective to distinguish HER2 status however more 
importantly its expression can be used to separate ER+ and ER- breast tumor tissues.  
Moreover, just like other isoforms its expression significantly differs between stage 
II and normal tissue. 
Overall, ANOVA applied to the average of all isoform gave a generic representation 
of CHRNA5 expression in cDNA panel, while stage II from Normals can be 
distinguished by this test (Table 4.9, Table 4.10). 
4.4.3 Comparison of CHRNA5 Isoform Expression 
After one-by-one analysis of CHRNA5 isoforms it was seen that subtyping only 
considering one isoform of the gene may not be as powerful as using multiple 
isoforms. Therefore, correlation between isoforms and how well they can distinguish 
receptor status should be analyzed.  
Expression values of each isoform (CHRNA5_v1, v2, v3) for cancer samples were 
plotted against each other after normalizing their Ct values with TPT 1 (∆Ct); each 
group in each plot was differently labeled to see whether clustering  between groups 
can be obtained or not (Figure 4.13).  
Figure 4.13 represents correlation plots of all three isoform considering normal vs 
tumor, ER+ vs ER-, HER2+ vs HER2- and three stages of breast cancer.  
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Figure 4.13: Correlation plots of three CHRNA5 isoforms 
 
For each correlation graph belonging to three isoforms, tumor and normal tissue, 
represented by red circle and black plus respectively, can easily be distinguished. 
Tumor samples have higher expression for each isoform than normal samples and 
they are almost always in different clusters. These graphs and findings also supports 
ANOVA test results represented in Table 4.9 and Table 4.10. 
ER status could be differentiated by CHRNA5 isoform v3 (Table 4.10) and plotting 
two isoforms across each other provided a better clustering of ER+ and ER- samples 
(Figure 4.13).  
HER2 status cannot be clearly differentiated by ANOVA or by correlation studies, 
CHRNA5 isoform expression does not seem differ significantly based on HER2 
status (Figure 4.13, Table 4.9). Considering average expression of all isoforms might 
be useful (Table 4.10). 
Breast cancer stages are important in diagnosis as well as for selecting treatment 
modality. For all genes, normal samples were different from one or more of the 
advancing stages; no two stages could be statistically significantly distinguished by 
CHRNA5 isoforms (Figure 4.13; Table 4.10).  However, combining stage II with 
stage III as a single group can help distinguish Normal, Stage I, and Stage II+III. 
Expression of isoforms was highly correlated to each other; correlation coefficients 
can be seen in Table 4.11. Overall, CHRNA5_v1 and CHRNA5_v3 were more 
correlated with each other than they were with CHRNA5_v2. At least one isoform of 
CHRNA5 was able to distinguish between ER- tumors from ER+ and ER- tumors 
had higher expressions in general. CHRNA5 has emerged an important tumor vs. 
normal marker in breast cancer (as it was shown in lung cancer) for all isoforms (v2 
and v3; and v1 for multiple isoforms) tested here. Analysis of clinical parameters in 
combination might reveal further details about the isoform specificity and diagnostic 
potential for CHRNA5 (e.g., ER status together with stage or HER2 status).  
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Table 4.11: Correlation coefficiencies and p-values between primer pairs for all samples 
 Gene pairs 
 v1-v2 v1-v3 v2-v3 
Corr. coef  0.5317 0.8149 0.6926 
Corr. p-value 0.0001 0.0000 0.0000 
4.4.4 GUI Application for cDNA Panel Data Analysis 
cDNA panels have large number of samples that are tested in replicates. 
Furthermore, multiple panels for the same set of samples can be studied for one or 
more genes. It is important to automatize the labeling, normalization, statistical 
analysis and graphical visualization steps in a cDNA panel qPCR analysis. However, 
there is not a useful application for this purpose in the literature thus we aimed to 
develop a GUI that will allow for input, quality control, selection of methods, and 
analysis and visualization of results in a modular manner. The application herein 
consists of four main parts; INPUT, QUALITY_CONTROL, METHOD, 
ANALYSIS.  
A pre-module presents options to normalize each target gene with their own 
reference from the same cDNA panel dilution (paired) or analyze them simply by 
using the average of expression values for a gene from different runs (dilutions) 
(unpaired). In the present thesis, the analyses were performed using the unpaired 
option. INPUT is where the user gives the input data in a certain format (e.g., 
131024_TPT1_cDNAPanel3.xlsx) and then the application allows user to enter 
datasets as individual files (Figure 4.14, Figure 4.15). 
After taking input, quality control module is presented and the current application 
has an option for checking the consistency of Tm, if user wants to apply this option 
(Figure 4.16).  
Methods module can be chosen as the third part of application. Efficiency of 
analyzed primer should be entered and either ∆∆Ct or ∆Ct methods can be chosen to 
analyze the expression data with primer amplification efficiency correction (Figure 
4.17). 
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Last phase of the application is to choose analysis type. ANOVA, Kruskal Wallis 
with or without multiple comparison tests can be chosen. The source of variation can 
be decided based on the column values of the given covariate description file that 
corresponds to the labels of each well in the analysis (e.g., receptor status or stages). 
Moreover, correlation of genes entered as target genes can be plotted. All data are 
analyzed after clicking ANALYZE button and published (Figure 4.18). 
 
Figure 4.14: Interfaces of input module of cDNA panel analysis application 
 
Input module allows user to enter input for both reference gene and target genes 
desired to be analyzed. After entering the repetition number of experiments for both 
reference gene and target genes windows corresponding to each experiment will 
appear; first one would be for reference gene (Figure 4.15); the window has empty 
areas to enter file names. After clicking “OK” other windows will appear to enter 
input file names of target genes or both target genes and their references. 
  
Figure 4.15: Interface to enter input file names 
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Figure 4.16: Interfaces of quality control module of cDNA panel analysis application 
 
This second module allows user to control quality of the data. Tm values can be 
checked with the method defined above. After checking Tm of data and excluding Ct 
values with outlier Tm values, the Ct data showing excluded and included Ct values 
can be exported into an excel file created with the same file name with program 
automatically.  
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Figure 4.17: Interfaces of method option module of cDNA panel analysis application 
 
Method module is to choose analysis method for raw data. After entering efficiency 
value for primer of target gene, module can process raw data using ∆∆Ct or ∆Ct 
methods. 
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Figure 4.18: Interfaces of analysis module of cDNA panel analysis application 
 
Last module finalizes the analysis of cDNA panel; it has options to choose groups for 
analysis based on the covdesc (covariate description file) to include groups defined 
by user. After determining which groups to compare and statistical analysis method, 
“ANALYZE” button gives boxplots and p-values for introduced data. This module 
will be have added functionality in the future for use of other ORIGENE panels in 
the GUI. 
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5. CONCLUSION AND DISCUSSION  
Breast cancer is one of the leading reasons of cancer causing death and there are still 
uncovered mechanisms related with breast cancer initiation, growth and invasion. In 
this study, a target gene, CHRNA5, thought to be playing a role in breast cancer was 
tested as a potential biomarker for normal vs cancer and subtype diagnosis in breast 
cancers in vivo. Furthermore, its association with ER receptor status and Estrogen 
responsiveness were studied using in vitro breast cancer cell lines. 
Alternative splicing was previously associated with a variety of diseases, including 
cancer. Splicing products, isoforms, of pre-mRNAs can lead to malignancy by the 
production of variants that are not normally present in a tissue type, or by changing 
the normal ratio between natural variants in a specific tissue 
51,54,76
. 
CHRNA5 is a subtype of nAChR that has previously been associated with 
neurological diseases such as Alzheimer, Parkinson, epilepsy as well as smoking 
behavior and cancer 
42
. CHRNA5 was also found to be alternatively spliced in cell 
lines, normal lung tissue and lung adenocarcinoma and the level of expression of 
CHRNA5 isoforms has been found as increased in lung cancer 
44
.  
All of these findings have led our research to focus on alternative splicing patterns of 
CHRNA5 in defining breast cancer subtypes and in response to β-estradiol (E2), 
tamoxifen (4-OHT) treatment and long term estrogen depletion. Studies were done 
with two different breast cancer cell lines, MCF7 (Luminal A) and MDA MB 
231(Basal-like) and an OriGene breast cancer cDNA panel 
10
.  
Our first approach to observe the modulatory effects of E2 on CHRNA5 isoform 
expression and breast cancer was through applying different doses of E2 to MCF7 
(ER+) and MDA MB 231 (ER-) cell lines. E2 is an agent playing a very important 
role in carcinogenesis of ER+ tumors; and it upregulates expression of certain genes, 
such as PS2/TFF1 
23,77
. However, dose-depending effects of E2 on CHRNA5 isoform 
expression in ER+ and ER- breast cancer cell lines have not been studied using 
qPCR in the literature yet. In this study, 1nm, 10nm, 100nm and 1000nm E2 were 
applied to the cancer cells that differ in their ER status for 24h after growing cells in 
E2 depleted medium and upon syncronization. Our results showed that the response 
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of cell lines to E2 treatment was completely different for ER+ and ER- cell lines 
while the response to different doses varies from gene to gene (Table 4.1). Then cell 
lines were analyzed separately for each CHRNA5 isoform and PS2 (TFF1). 
Expression of genes of interest in ER+ MCF7 cell line showed an upregulated trend 
with increasing E2 dose. Only expression of CHRNA_v3 did not regularly increase 
with increasing E2 dose (Figure 4.2).    
In ER- cell line MDA-231 PS2 also increased to a lesser degree also its expression 
pattern was not directly correlated with increasing E2 doses degree. Previous studies 
also show that PS2 can increase in ER- cell lines (Figure 8.5) 
78
.  Moreover, PS2 (a 
gene in the downstream of ER pathway) expression increases with dosage 
confirming reliability of experiment in MCF7. Our ∆Ct analysis of CHRNA5 and 
PS2 using clustering it is apparent that ER- cell line MDA-MD-231 expresses PS2 at 
much lower levels than MCF7. Expression of some of the genes decreased or showed 
a fluctuating expression pattern with changing dose of E2 (Figure 4.3). Heatmap of 
CHRNA5 isoforms and PS2 expression, also, presents the increase in gene 
expression in MCF7 and varying pattern in MDA MB 231 cell line (Figure 4.4). 
In ER+ cell line, E2 can bind as ligand to the ER; ER pathway either genomic or 
non-genomicaly causes an increase in expression of a group of genes that targets of 
ER pathway. Supported by our results, it can be interpreted that CHRNA5 expression 
could be one of the genes whose expression is regulated by ER pathway activation. It 
is a possibility that E2 in combination with ER binds to the CHRNA5 promoter 
directly or indirectly. Previous studies suggested that effect of E2 on CHRNA5 is 
secondary since cycloheximide, a translational inhibitor, prevented the increase in 
expression of CHRNA5 upon E2 treatment 
49
; future studies should include treatment 
with cycloheximide to validate this aspect of interaction between ER pathway and 
CHRNA5 expression. 
We, then, decided to study the effect of E2 in the presence of tamoxifen (4-OHT), 
ER antagonist which prevents E2 to bind to ER 
32
. In the presence of 4-OHT, ER+ 
cell lines was expected to behave like the ER- cell line in terms of gene expression 
changes. The question here was whether E2 when given with tamoxifen has a 
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reduced effect on the target genes’ expression, e.g., PS2 and FOSL2, together with 
CHRNA5 isoforms.  
Our results indicated that 4-OHT was significantly effective in decreasing all 
CHRNA5 isoforms’ expression we analyzed except CHRNA5_v3. Previous 
experiments showed that some of CHRNA5 isoforms were upregulated with E2 
treatment; with this study for the first time we showed that 4-OHT reduced the 
CHRNA5 expression in the opposite direction of E2. PS2 expression graph also 
confirmed effectivity of E2 although to a lesser degree than the previous experiment 
(Figure 4.2, Figure 4.5). Bioinformatics studies show that, PS2 expression increases 
with E2 and decreases with 4-OHT+E2 (Figure 8.3). However in our results, PS2 
showed almost same expression level with E2 treatment after E2+4-OHT treatment 
(Figure 4.5). This may indicate tamoxifen resistance or incompetency between dose 
of E2 and tamoxifen. We therefore examined expression of FOSL2, expected to 
increase in 4-OHT+E2 in sensitive and resistant cell lines (although to differing 
degrees; Figure 8.1 and Figure 8.6).  Bioinformatics studies showed that FOSL2 
expression with 4-OHT treatment was half of its expression with E2 or E2+4-OHT 
treatment 
75
 (Figure 8.1) in 4-OHT sensitive cell lines. Our result for FOSL2 
expression by qPCR did not yield significance (Figure 4.5). However, in order to be 
certain about tamoxifen sensitivity of our cell line other genes from GDS1094 and 
GDS4051 dataset should be chosen and their expression levels should be analyzed. 
Furthermore, different dose combinations of 4-OHT and E2 as well as different 
batches of MCF7 cell lines while increasing sample size can be used for a better 
understanding of the 4-OHT response of CHRNA5. 
Some CHRNA5 isoforms did not show a remarkable increase with E2 treatment, 
while others were affected by E2 in positive way. In particular, expression of 
CHRNA5_v2 did not show the same increase rate with “Effects of Different Doses 
of E2 on CHRNA5 Isoform Expression” experiment.  It may indicate that 10nm E2 
was not that that efficient for this set of experiments. However, in every case, E2+4-
OHT treatment is able to revert the effect of 4-OHT; the gene expression levels were 
very close to those of E2 treated samples after E2+ 4-OHT treatment (Figure 4.5).  
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PS2, CHRNA5_v1 and CHRNA5_iso3 gene expressions changed significantly 
between E2 and 4-OHT treatment also 4-OHT treatment resulted in a significant 
expression change compared to control group in PS2 and CHRNA5_v1 genes (Table 
4.6, Table 4.7). This also suggests that identification of CHRNA5 isoform expression 
might be useful in in vivo diagnosis studies that include samples with different ER 
status and also for patients with or without tamoxifen treatment. 
“Effects of 4-OHT and E2 Treatment” experiment showed that 4-OHT treatment can 
significantly reduce the expression of a set of genes that are found to be related with 
breast cancer; however in the presence of E2 this decline in the expression of these 
genes can be rescued. This, again, supported the hypothesis that CHRNA5 
expression was affected by ER pathway activation; presence of E2 induces an 
increase in transcription of CHRNA5 gene even in co-treatment with 4-OHT, which 
may also point out to resistance developed in vitro.  
To further examine the effects of E2 depletion on breast cancer, ER+ breast cancer 
cell line (MCF7) has been exposed to long-term E2 depletion (LTED). It may be 
simply thought that without E2 breast cancer related gene set expression may 
decrease, however previous studies show that this is not the case. After a long term 
depletion of E2, breast cancer cells find a way to compensate the lack of E2 
34,36
.  
In our study, we applied LTED for 6 months along with a control group including E2 
1nm/ml (10nm) added manually. The main result from this experiment was that 
ESR1 expression significantly increased over time and was consistently higher than 
the control after time (Table 4.9). 
During about first fifteen days of experiment, a difference can be observed in 
expression levels between control and LTED group, however after approximately 
first month of experiment the difference between control and LTED group has been 
closed; LTED group became control group like, the lack of E2 started not to affect 
expression of genes of interest (Figure 4.8).    
In sixth months, there was almost no difference between control and LTED groups 
except ESR1 and PS2 genes. However, the increasing trend in the level of gene 
expression with the LTED can be observed. LTED experiment revealed an 
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interesting phenomenon related to E2- breast cancer relationship. In the absence of 
E2, first, cells decrease the expression of genes, whose regulations and expressions 
affected by ER pathway. However, after LTED, these genes increase their 
expressions. This phenomenon may be explained with the increase in ESR1 
expression, in the absence of E2 cells might want to compensate this depletion and 
start to compensate by increasing their estrogen receptor expression with a feedback 
mechanism. One of the most common hypotheses for the mechanism behind ESR1 
upregulation is that, following E2 deprivation, growth factor signaling cross-talk 
modulates ESR1, turning it into a supersensitive receptor able to regulate 
transcription in the presence of traces of estrogens or even independently of them 
36
. 
With increasing levels of the receptor, ER pathway may be activated with other 
estrogen derivatives and ligands. GEO2R analysis and our results show that ESR1 
expression significantly increases in the absence of E2 (Figure 1.3). This 
upregulation at the level of estrogen receptor may cause the increase in the level of 
expression of genes on the downstream of ER pathway such as PS2 and CHRNA5 
(Figure 8.4). In our results, the level of PS2 increased towards the third month but 
then decreased again, however it was still higher than first two months (Figure 4.9). 
At the end of 6-month LTED course we obtained an LTED isogenic MCF7 cell line 
for further studies. 
Panel studies are also a part of expression analysis studies and research on cancer 
diagnosis. Cancer subtyping should include a very large sample size for reliable 
prediction of disease status and treatment modality as well as interpretation of the 
data statistically. In order to study how different isoforms of CHRNA5 gene were 
expressed in different subtypes of breast cancer (ER+/-; HER2+/-; and stage N-I-II-
III) a breast cancer cDNA panel from OriGene was examined.  
ANOVA results showed that CHRNA5 isoforms distinctly had different expression 
levels in normal and breast tumor samples. This was highly significant for all tested 
isoforms. To see whether CHRNA5 gene can be used for subtyping, ER, HER2 
status and tumor stages were also examined.  CHRNA5_v3 was seen as a good 
candidate to distinguish ER- and ER+ breast tumor. Also stages can be separated 
with the differences at the level of CHRNA5 isoforms but only in comparison with 
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the normals for most cases. HER2 status was not significantly distinguished with a 
single CHRNA5 isoform expression level based on ANOVA results. 
After one-by-one analysis of CHRNA5 isoform expression, we decided to analyze 
the correlation between isoforms in a pairwise fashion in their ability to distinguish 
receptor status. ER status cannot be distinguished with every single CHRNA5 
isoform; however, coplots of two isoforms at once give a more detailed idea to 
distinguish ER status with CHRNA5 isoform expression. This suggests that 
combination of CHRNA5 isoform expression may closely predict ER status in breast 
cancer. Future analyses might include Principal Component Analysis or MANOVA. 
As a result, ER+ samples were observed to have relatively lower level of CHRNA5 
expression for three isoforms. Between three correlation graphs between 
CHRNA5_v1, CHRNA5_v2 and CHRNA5_v3, CHRNA5_v3- CHRNA5_v2 pairs, 
respectively, the latter gives the most separated clusters of ER+ and ER- (Figure 
4.13). Indeed these two isoforms correspond to the long and short forms of the 
CHRNA5 mRNA and are spliced from the same transcript with exclusion/inclusion 
of Exon V while CHRNA5_v1 amplicon corresponds to multiple isoforms that 
include these two and possibly others; thus this indicates that use of specific primers 
corresponding to a specific form of the transcript might help increase the diagnostic 
potential of candidate genes in cancer. Moreover, ANOVA results indicated 
CHRNA5_v3 can distinguish ER- and ER+ tumor samples making this isoform 
suitable for future studies with larger cDNA panels (Table 4.11). HER2 status could 
not be clearly differentiated by univariate tests or correlation studies. Also, no clear 
separation can be obtained to distinguish tumor stage with CHRNA5 isoform 
expression level, but CHRNA5 expression trend for each isoform showed an increase 
while stage was increasing. Regression analyses on stage might help statistically test 
this trend observed in the graphs. 
cDNA panel analysis experiment showed that CHRNA5 isoform expression 
increased in breast tumor compared to normal breast tissue, similar to lung cancer 
44
. 
Also, different level of expression of CHRNA5 isoforms may help distinguish 
different subtypes of breast cancer. Considering more than one isoform of CHRNA5 
at a time maybe more effective for distinguishing ER status in breast cancer. 
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As a part of cDNA panel analysis, data quality and reliability are important issues to 
consider. For this purpose a new approach has been developed by checking melting 
temperature (Tm) of every sample for each primer. Analysis with or without Tm 
check is compared and it was observed that outlier number and the range of Ct 
remarkably decreased with Tm check (Figure 4.12). When melting curves from data 
were examined by PCR, we have seen a shift from the expected amplicon size with 
deviation from the median Tm of the cDNA panel. Melting curves should be uniform 
for each cycle of PCR, because the reaction happening in each cycle for one specific 
primer should be the same unless it amplifies another sequence rather than the 
amplicon of interest 
79
. 
A workflow was then established for OriGene Breast cancer cDNA panel quality 
control, normalization, statistical analysis, and data visualization using multiple 
cDNA panel dilutions by integrating the above mentioned analyses into a GUI using 
MATLAB. This application was presented as an automated expression analysis tool 
which makes data quality and analysis much easier to handle and report the results 
with given options to select from (e.g., ANOVA vs. Kruskal-Wallis; delta-CT or 
deltadeltaCt methods; selection of clinical parameters to perform tests). The GUI 
presented in this study thus allows for comparison of methods while providing a 
platform to analyze any OriGene cDNA panel since it is possible to customize the 
analyses based on the columns that include clinical parameters for cancer subtypes. 
This tool is important because it is the first freely available tool developed to process 
that detailed analysis for cDNA panels. Finally, it reduces the time spent for analysis 
and possibility to introduce mistakes by handling the data manually. 
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6. FUTURE PERSPECTIVES  
For further studies to reveal effects and regulatory function of CHRNA5 gene 
expression on breast cancer, we studied ER pathway related factors effecting to 
CHRNA5 expression and regulation. 
It is known that CHRNA5 expression can be altered by the changes in expression 
level of nearby genes, they are co-regulated 
47
. Expression of these genes and their 
relationship with different subtypes of breast cancer can be studied and analyzed in 
the future. Such a gene set maybe a biomarker set for diagnosis of breast cancer 
subtypes. Also it is known that some of these genes, such as IREB2,  have already 
played a role in breast cancer initiation and growth 
42
. Therefore, to reveal nAChRs – 
breast cancer relationship along with CHRNA5, genes such as CHRNA4, CHRNB3, 
and PSMA4 (a chromosomal neighbor) should be studied. 
Moreover, to obtain a more detailed profile covering CHRNA5 expression - subtype 
relationship different cDNA panels can be studied. This can both increase sample 
size and variation in the cohort resulting in a more realistic estimate of the 
association. Also, new isoforms of CHRNA5 can be revealed with Northern blot 
studies. 
To further assess E2-CHRNA5 relationship, experiments with different doses and 
time-points of E2 in the absence and presence of cycloheximide can be designed. 
This could help validation of a previous hypothesis suggesting that effects of E2 on 
CHRNA5 are secondary 
49
. Also, different doses of 4-OHT and other ER antagonist 
should be tested on ER+ cell lines to obtain the exact dose and the most effective 
molecule to suppress effect of E2 on CHRNA5 expression and breast cancer. 
In this study only two cell lines were used, however to further examine response of 
ER+ and ER- breast cancer cells to E2 and 4-OHT and indirectly on CHRNA5 
expression, more than two cell lines including both ER+ and ER- ones could be 
studied. 
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Effects of E2 and/or 4-OHT on cells treated with an siRNA or an overexpression 
vector for CHRNA5 could also be studied to determine the importance of CHRNA5 
expression both at the mRNA and protein level on ER signaling.  
In addition to in vitro studies, in vivo approaches should be used; for example, 
injecting an overexpression vector or siCHRNA5 to a model organism proper to 
study breast tumor formation or changes in the size and invasiveness of tumor can be 
studied. Rodents can be a good choice to study breast cancer because of their high 
number of breasts. 
Tissue microarrays (TMAs) including tissues from breast tumors can be studied for 
changes in protein expression of CHRNA5. Detecting location and density of 
CHRNA5 by labeling them with specific CHRNA5 Ab in different types and stages 
of breast cancer tissue can give an insight into the importance of this gene in 
diagnosis. 
Finally, the GUI application designed herein can be extended by adding more options 
and module interfaces and can be made more appealing using different programs. 
The processing of template covariate description file also can generalized so that user 
may use the GUI on different cDNA panels with different sample arrangement, type 
and clinical characteristics.  
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Appendix A 
Covdesc File 
Table 8.1: Covdesc file of cDNA panel 
qPCRwell PatientID Replicate Tumor ER PR HER2 Stage 
A1 C1 1 0 5 5 5 5 
A2 C2 1 0 5 5 5 5 
A3 C3 1 0 5 5 5 5 
A4 C4 1 0 5 5 5 5 
A5 C5 1 0 5 5 5 5 
A6 C6 1 0 5 5 5 5 
A7 C7 1 0 5 5 5 5 
A8 C8 1 1 0 0 0 1 
A9 C9 1 1 1 1 0 1 
A10 C10 1 1 0 0 0 1 
A11 C11 1 1 1 1 1 1 
A12 C12 1 1 0 1 0 1 
B1 C1 2 0 5 5 5 5 
B2 C2 2 0 5 5 5 5 
B3 C3 2 0 5 5 5 5 
B4 C4 2 0 5 5 5 5 
B5 C5 2 0 5 5 5 5 
B6 C6 2 0 5 5 5 5 
B7 C7 2 0 5 5 5 5 
B8 C8 2 1 0 0 0 1 
B9 C9 2 1 1 1 0 1 
B10 C10 2 1 0 0 0 1 
B11 C11 2 1 1 1 1 1 
B12 C12 2 1 0 1 0 1 
C1 D1 1 1 1 1 1 1 
C2 D2 1 1 NaN NaN NaN 1 
C3 D3 1 1 0 0 1 1 
C4 D4 1 1 1 1 0 1 
C5 D5 1 1 NaN NaN NaN 1 
C6 D6 1 1 1 1 1 2 
C7 D7 1 1 0 0 0 2 
C8 D8 1 1 0 NaN 0 2 
C9 D9 1 1 0 0 1 2 
C10 D10 1 1 1 1 0 2 
C11 D11 1 1 1 1 0 2 
C12 D12 1 1 0 0 1 2 
D1 D1 2 1 1 1 1 1 
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D2 D2 2 1 NaN NaN NaN 1 
D3 D3 2 1 0 0 1 1 
D4 D4 2 1 1 1 0 1 
D5 D5 2 1 NaN NaN NaN 1 
D6 D6 2 1 1 1 1 2 
D7 D7 2 1 0 0 0 2 
D8 D8 2 1 0 NaN 0 2 
D9 D9 2 1 0 0 1 2 
D10 D10 2 1 1 1 0 2 
D11 D11 2 1 1 1 0 2 
D12 D12 2 1 0 0 1 2 
E1 E1 1 1 1 0 0 2 
E2 E2 1 1 0 0 0 2 
E3 E3 1 1 0 0 1 2 
E4 E4 1 1 1 1 0 2 
E5 E5 1 1 NaN NaN 1 2 
E6 E6 1 1 NaN NaN NaN 2 
E7 E7 1 1 0 1 0 2 
E8 E8 1 1 NaN NaN NaN 2 
E9 E9 1 1 1 1 1 2 
E10 E10 1 1 0 NaN 0 2 
E11 E11 1 1 1 1 1 2 
E12 E12 1 1 0 0 0 2 
F1 E1 2 1 1 0 0 2 
F2 E2 2 1 0 0 0 2 
F3 E3 2 1 0 0 1 2 
F4 E4 2 1 1 1 0 2 
F5 E5 2 1 NaN NaN 1 2 
F6 E6 2 1 NaN NaN NaN 2 
F7 E7 2 1 0 1 0 2 
F8 E8 2 1 NaN NaN NaN 2 
F9 E9 2 1 1 1 1 2 
F10 E10 2 1 0 NaN 0 2 
F11 E11 2 1 1 1 1 2 
F12 E12 2 1 0 0 0 2 
G1 F1 1 1 NaN NaN NaN 2 
G2 F2 1 1 0 0 1 3 
G3 F3 1 1 0 NaN 0 3 
G4 F4 1 1 1 1 0 3 
G5 F5 1 1 1 0 1 3 
G6 F6 1 1 1 1 0 3 
G7 F7 1 1 0 0 0 3 
G8 F8 1 1 NaN NaN NaN 3 
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G9 F9 1 1 0 1 0 3 
G10 F10 1 1 NaN NaN 0 3 
G11 F11 1 1 1 1 0 3 
G12 F12 1 1 1 0 0 3 
H1 F1 2 1 NaN NaN NaN 2 
H2 F2 2 1 0 0 1 3 
H3 F3 2 1 0 NaN 0 3 
H4 F4 2 1 1 1 0 3 
H5 F5 2 1 1 0 1 3 
H6 F6 2 1 1 1 0 3 
H7 F7 2 1 0 0 0 3 
H8 F8 2 1 NaN NaN NaN 3 
H9 F9 2 1 0 1 0 3 
H10 F10 2 1 NaN NaN 0 3 
H11 F11 2 1 1 1 0 3 
H12 F12 2 1 1 0 0 3 
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Appendix B 
GeoDataSet Graphs 
 
Figure 8.1: GEO2R analysis of GSE26459 dataset for FOSL2 expression with E2 and 4-OHT in 
4-OHT sensitive cell lines. 
 
Figure 8.2: GEO2R analysis of GSE26459 dataset for CHRNA5 expression with E2 and 4-OHT 
in 4-OHT sensitive cell lines. 
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Figure 8.3: GEO2R analysis of GSE26459 dataset for PS2 expression with E2 and 4-OHT in 4-
OHT sensitive cell lines. 
 
Figure 8.4: GEO2R analysis of GSE20361 dataset for PS2 expression after and before LTED. 
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Figure 8.5: GEO2R analysis of GSE2251 dataset for PS2 expression with and without E2 
treatment in ER- MDA MB 231 cell line. 
 
 
Figure 8.6: GEO2R analysis of GSE26459 dataset for FOSL2 expression with E2 and 4-OHT in 
4-OHT resistant cell lines. 
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Appendix C 
Time Point Table for LTED Experiment 
Table 8.2: Time points for LTED experiment 
Sample Collection date Experimental date 
1 12.12.13 1 
2 25.12.13 13 
3 10.01.14 29 
4 14.01.14 33 
5 27.01.14 46 
6 13.02.14 63 
7 17.02.14 67 
8 26.02.14 76 
9 10.03.14 88 
10 05.05.14 150 
11 13.05.14 158 
12 19.05.14 164 
13 25.05.14 170 
14 03.06.14 180 
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